[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 872
1. Bellomi M, Rampinelli C, Funicelli L, Veronesi G: Screening for lung cancer. Cancer Imaging; 2006;6:S9-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Screening for lung cancer.
  • The lethality of lung cancer is related to the advanced stage at diagnosis.
  • Initial studies have demonstrated that screening computed tomography (CT) is effective in diagnosing lung cancer at an earlier stage when compared with current clinical practice, however the best clinical approach for screening detected nodules has to be defined.
  • The prevalence of lung cancer in the screened population is 1.1%-2.7%, and the incidence is 0.2%-1.1%.
  • The percentage of surgery performed for benign lesions ranges from 21% to 55%.
  • The results of randomized clinical studies, when available, will assess the real efficacy of CT in reducing lung cancer related mortality.
  • [MeSH-major] Lung Neoplasms / radiography. Mass Screening. Tomography, Spiral Computed
  • [MeSH-minor] Aged. Algorithms. Biopsy, Fine-Needle. Case Management. Female. Humans. Incidence. Lung Diseases / radiography. Lung Diseases / surgery. Male. Middle Aged. Positron-Emission Tomography. Prevalence. Risk Factors. Smoking. Solitary Pulmonary Nodule / pathology. Solitary Pulmonary Nodule / radiography. Survival Analysis. Thoracic Surgery, Video-Assisted. Tumor Burden. Unnecessary Procedures / statistics & numerical data

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) International Cancer Imaging Society.
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2474-82 [11147630.001]
  • [Cites] Chest Surg Clin N Am. 2000 Nov;10(4):653-61 [11091918.001]
  • [Cites] JAMA. 2001 Feb 21;285(7):914-24 [11180735.001]
  • [Cites] Cancer. 2001 Jul 1;92(1):153-9 [11443621.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(14):1759-67 [11549429.001]
  • [Cites] Eur Radiol. 2001;11(10):1975-85 [11702131.001]
  • [Cites] AJR Am J Roentgenol. 2002 May;178(5):1053-7 [11959700.001]
  • [Cites] Radiology. 2002 Dec;225(3):823-8 [12461267.001]
  • [Cites] JAMA. 2003 Jan 15;289(3):313-22 [12525232.001]
  • [Cites] Chest. 2003 Aug;124(2):614-21 [12907551.001]
  • [Cites] Lancet. 2003 Aug 23;362(9384):593-7 [12944057.001]
  • [Cites] Eur Radiol. 2003 Oct;13(10):2378-83 [12743736.001]
  • [Cites] Radiology. 2004 Apr;231(1):164-8 [14990809.001]
  • [Cites] Chest. 2004 Apr;125(4):1522-9 [15078769.001]
  • [Cites] Chest. 2004 May;125(5 Suppl):158S-62S [15136487.001]
  • [Cites] JAMA. 1973 Jun 4;224(10):1361-5 [4739985.001]
  • [Cites] Am Rev Respir Dis. 1984 Oct;130(4):561-5 [6091507.001]
  • [Cites] Chest. 1992 Apr;101(4):1013-8 [1313349.001]
  • [Cites] AJR Am J Roentgenol. 1995 Mar;164(3):603-7 [7863879.001]
  • [Cites] Eur Radiol. 1998;8(4):609-14 [9569333.001]
  • [Cites] Radiology. 2000 Jan;214(1):73-80 [10644104.001]
  • [Cites] Chest. 2000 Feb;117(2):374-9 [10669677.001]
  • [Cites] Lung Cancer. 2000 Aug;29(2):105-24 [10963841.001]
  • [Cites] Radiology. 2000 Oct;217(1):251-6 [11012453.001]
  • [Cites] Lancet. 1998 Apr 25;351(9111):1242-5 [9643744.001]
  • [Cites] Radiology. 1998 Oct;209(1):243-9 [9769838.001]
  • [Cites] Eur Radiol. 1999;9(2):281-6 [10101651.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Lung Cancer. 2004 Aug;45 Suppl 2:S13-9 [15552777.001]
  • [Cites] Radiology. 2004 Dec;233(3):793-8 [15498895.001]
  • [Cites] Radiology. 2005 Apr;235(1):259-65 [15695622.001]
  • [Cites] Eur Radiol. 2005 Oct;15(10):2064-9 [16003507.001]
  • [Cites] Radiology. 2005 Nov;237(2):395-400 [16244247.001]
  • [Cites] Radiology. 2005 Nov;237(2):675-83 [16244276.001]
  • [Cites] Radiology. 2006 Apr;239(1):34-49 [16567482.001]
  • [Cites] Cancer. 2000 Dec 1;89(11 Suppl):2506-9 [11147637.001]
  • (PMID = 17114084.001).
  • [ISSN] 1470-7330
  • [Journal-full-title] Cancer imaging : the official publication of the International Cancer Imaging Society
  • [ISO-abbreviation] Cancer Imaging
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC1805071
  •  go-up   go-down


2. Wang B, Zhang DC, Cheng GY, He J: [Diagnosis and surgical treatment of inflammatory pseudotumor of the lung: a report of 51 cases]. Ai Zheng; 2005 Feb;24(2):219-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis and surgical treatment of inflammatory pseudotumor of the lung: a report of 51 cases].
  • BACKGROUND & OBJECTIVE: Clinical symptoms and imaging presentations of inflammatory pseudotumor of the lung (IPL) lack of specialties, and always result in misdiagnoses.
  • This article was to summarize features of IPL, and to improve diagnosis accuracy and appropriate operation selection.
  • RESULTS: Of the 51 patients, before operation, only 3 (5.9%) had been correctly diagnosed, 24 (47.1%) were suspected having tuberculoma or other benign lung tumors, 10 (19.6%) with undefined occupied lesion in the lung, 14 (27.4%) were misdiagnosed as lung cancer.
  • All patients received surgery, including lobectomy in 23 patients (45.1%), tumor excision in 22 patients (43.1%), wedge resection in 4 patients (7.8%), and segmental resection in 2 patients (3.9%).
  • [MeSH-major] Plasma Cell Granuloma, Pulmonary / diagnosis. Plasma Cell Granuloma, Pulmonary / surgery. Pneumonectomy / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Lung Neoplasms / diagnosis. Male. Middle Aged. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15694038.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


3. Burdick MJ, Jolles PR, Grimes MM, Henry DA: Mediastinal hibernoma simulates a malignant lesion on dual time point FDG imaging. Lung Cancer; 2008 Mar;59(3):391-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Dual time point 2-deoxy-2-[18F] fluoro-d-glucose (FDG) positron emission tomography (PET) imaging has been shown to be useful in helping differentiate benign from malignant lesions.
  • Biopsy proved the lesion to represent a hibernoma, an uncommon benign fatty tumor.
  • This case exemplifies the complexity of tissue metabolic properties, and the difficulty in establishing absolute criteria for benign and malignant processes.
  • [MeSH-minor] Diagnosis, Differential. Fluorodeoxyglucose F18. Humans. Male. Mediastinal Neoplasms / radionuclide imaging. Middle Aged. Radiopharmaceuticals

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17905469.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


Advertisement
4. Wu YJ, Hao YH, Wu WC, Wu YM: [Value of auto-fluorescence spectrum combined with tumor markers in diagnosis of lung cancer]. Guang Pu Xue Yu Guang Pu Fen Xi; 2009 Oct;29(10):2787-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of auto-fluorescence spectrum combined with tumor markers in diagnosis of lung cancer].
  • To improve the diagnostic efficiency of cancer, serum fluorescence spectrum combined with tumor marker groups was proved more powerful, especially when used with mathematical evaluation model, that is, artificial neural network (ANN) modeling.
  • ANN modeling is very suitable for the discrimination of lung cancer.
  • In the present paper, serum fluorescence spectrum was applied to study the difference among normal, benign and malignant groups and develop the relevant method of determination.
  • On the other hand, combined with tumor markers, CEA, NSE, SCC-Ag, CYFRA21-1 and p16 methylation, artificial neural network and Fisher linear discriminatory analysis were used to develop the prediction models of diagnosis of lung cancer, and compared by ROC.
  • It was shown that the result of the fluorescence spectrum combined with tumor markers based on ANN model is superior to that of the fluorescence spectrum ANN model.
  • [MeSH-major] Biomarkers, Tumor. Neural Networks (Computer)
  • [MeSH-minor] Fluorescence. Humans. Lung Neoplasms

  • Genetic Alliance. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20038061.001).
  • [ISSN] 1000-0593
  • [Journal-full-title] Guang pu xue yu guang pu fen xi = Guang pu
  • [ISO-abbreviation] Guang Pu Xue Yu Guang Pu Fen Xi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


5. Balduyck B, Lauwers P, Govaert K, Hendriks J, De Maeseneer M, Van Schil P: Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report. J Thorac Oncol; 2006 Jul;1(6):588-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura with associated hypoglycemia: Doege-Potter syndrome: a case report.
  • Tumor-associated hypoglycemia as a paraneoplastic phenomenon is a well-known entity and is referred to as Doege-Potter syndrome.
  • On transthoracic puncture, a tumor of pleural origin was diagnosed.
  • This tumor, presenting as a large, well-circumscribed encapsulated mass, was removed by thoracotomy.
  • On pathologic examination, the diagnosis of a solitary fibrous tumor with benign characteristics was made.
  • Solitary fibrous tumors are localized tumors of the pleura with an unpredictable behavior.
  • [MeSH-minor] Aged. Biopsy, Needle. Bronchoscopy. Follow-Up Studies. Humans. Immunohistochemistry. Male. Neoplasm Staging. Radiography, Thoracic. Thoracotomy / methods. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Potter syndrome.
  • Genetic Alliance. consumer health - Hypoglycemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17409923.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


6. Budhu AS, Zipser B, Forgues M, Ye QH, Sun Z, Wang XW: The molecular signature of metastases of human hepatocellular carcinoma. Oncology; 2005;69 Suppl 1:23-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The current metastasis paradigm suggests that the primary tumor starts off benign but over time slowly acquires changes that provide a few rare cells within the tumor the ability to metastasize.
  • Similar findings are also evident in primary cancers of the lung, breast, and prostate.
  • These findings imply that many of the metastasis-promoting genes are embedded in the primary tumors and that the ability to metastasize may be an inherent quality of the tumor from the beginning.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Neoplasm Metastasis / genetics
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biomarkers, Tumor / genetics. Gene Expression Profiling. Humans. Models, Biological. Osteopontin. Prognosis. Sialoglycoproteins / analysis. Sialoglycoproteins / physiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16210873.001).
  • [ISSN] 0030-2414
  • [Journal-full-title] Oncology
  • [ISO-abbreviation] Oncology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / SPP1 protein, human; 0 / Sialoglycoproteins; 106441-73-0 / Osteopontin
  • [Number-of-references] 21
  •  go-up   go-down


7. Hu Y, Li B, Song C: [Clinical research of perioperative serum VEGF and MMP-9 levels in patients with non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Oct 20;11(5):734-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical research of perioperative serum VEGF and MMP-9 levels in patients with non-small cell lung cancer.].
  • BACKGROUND: Angiogenesis is necessary in tumor progression and metastasis.
  • Elevated levels of VEGF and MMP-9 were reported in lung cancer.
  • The aim of this research is to study the dynamic changes of serum VEGF and MMP-9 levels in non-small cell lung cancer (NSCLC) patients who underwent surgery.
  • At the same time 18 patients with pulmonary benign diseases treated by surgery were studied as the control.
  • RESULTS: Preoperative serum VEGF levels (685.50 pg/mL) was significantly higher in the group of patients with NSCLC compared with the benign and healthy group (respectively: 160.90 pg/mL, 94.40 pg/mL) (P <0.01); Serum VEGF levels were elevated after surgery and the levels were 1055.60 pg/mL, 1533.90 pg/mL, 1882.10 pg/mL, respectively, on postoperative day 1, 7, 14 (P <0.01).
  • 2 Preoperative serum MMP-9 level (84.48 ng/mL) was significantly higher in the group of patients with NSCLC compared with the benign and healthy group (respectively: 58.98 ng/mL and 42.94 ng/mL, P <0.01); Serum MMP-9 levels were elevated soon after surgery and the peak (282.99 ng/mL) was observed on postoperative day 1 in NSCLC.
  • CONCLUSIONS: Preoperative serum VEGF and MMP-9 levels were both significantly higher in the group of patients with NSCLC compared with the benign and healthy group.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20738923.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


8. Cronin CG, Cashell T, Mhuircheartaigh JN, Swords R, Murray M, O'Sullivan GJ, O'Keeffe D: Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis. AJR Am J Roentgenol; 2009 Nov;193(5):W407-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone biopsy of new suspicious bone lesions in patients with primary carcinoma: prevalence and probability of an alternative diagnosis.
  • OBJECTIVE: We sought to assess the probability that a new suspicious bone lesion is an alternative diagnosis, that is, a benign lesion or a second malignant tumor as opposed to metastatic disease from the malignant tumor, in a person with known primary malignant disease.
  • The following parameters were recorded: indication, type of primary cancer, date of diagnosis, complications of biopsy, whether the sample was of diagnostic quality, pathologic finding, and thus whether the primary malignant tumor was concordant with the lesion sampled.
  • Cancer types included those of genitourinary tract, breast, thyroid, gastrointestinal tract, and lung and lymphoma and myeloma.
  • Forty-two of 43 positive biopsy findings (98%) were consistent with the primary malignant tumor.
  • The other positive finding was a new malignant tumor.
  • This new tumor was myelofibrosis in a man with chronic myelocytic leukemia.
  • The primary diagnosis correlated highly with that of the new bone lesion (Spearman's test, R = 0.842; p < 0.001).
  • CONCLUSION: In a patient with known primary malignant disease, the probability is low (2%) that biopsy of a new suspicious bone lesion will show the lesion is other than metastasis from the primary tumor.
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans. Male. Prevalence. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Biopsy.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19843719.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Lanuti M, De Delva PE, Gaissert HA, Wright CD, Wain JC, Allan JS, Donahue DM, Mathisen DJ: Review of superior vena cava resection in the management of benign disease and pulmonary or mediastinal malignancies. Ann Thorac Surg; 2009 Aug;88(2):392-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Review of superior vena cava resection in the management of benign disease and pulmonary or mediastinal malignancies.
  • BACKGROUND: Obstruction of the superior vena cava (SVC) by tumor or benign disease implies unreconstructable disease and poor outcome.
  • We analyzed the operative results, graft patency, and survival in patients undergoing SVC resection and reconstruction for benign disease and pulmonary or mediastinal malignancy.
  • METHODS: Patients undergoing SVC resection from 1997 to 2007 for surgical management of benign and invasive neoplasms were retrospectively reviewed.
  • Malignant disease was resected in 17: lung cancer in 9 and mediastinal malignancy in 8.
  • Two patients (10%) with benign processes required reconstruction for chronic SVC syndrome.
  • Five-year survival probability was 30% for patients with resected lung cancer and 56% for patients with resected anterior mediastinal malignancies.
  • CONCLUSIONS: Resection and reconstruction may be safely performed in selected patients for benign and malignant obstruction or infiltration of the SVC.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Lung Neoplasms / surgery. Mediastinal Neoplasms / surgery. Vena Cava, Superior / surgery

  • Genetic Alliance. consumer health - Pulmonary Disease.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2009 Aug;88(2):397-8 [19632381.001]
  • (PMID = 19632380.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


10. Chaplin A, Conrad DM, Tatlidil C, Jollimore J, Walsh N, Covert A, Pasternak S: Primary cutaneous PEComa. Am J Dermatopathol; 2010 May;32(3):310-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Microscopic examination of the excisional specimen revealed a dermal tumor composed of nests of epithelioid cells exhibiting clear cytoplasm.
  • The tumor showed an infiltrative border.
  • Immunohistochemical evaluation revealed that the tumor cells were positive for HMB-45 and microftalmia associated transcription factor (MITF).
  • The tumor cells were negative for S-100 protein, alfa smooth muscle actin, HHF-35, and various cytokeratins.
  • Pecomas are rare, recently described mesenchymal tumors composed of perivascular epithelioid cells.
  • They constitute a spectrum of lesions in different organs including angiomyolipoma of the kidney and liver, sugar tumor of the lung, lymphangiomatosis, and lymphangiomyoma.
  • Follow-up data is limited but they appear to behave in a benign fashion.
  • We report an additional case with the goal of alerting dermatopathologists to this distinctive unusual neoplasm.
  • [MeSH-minor] Antigens, Neoplasm / analysis. Biomarkers, Tumor / analysis. Biopsy. Desmin / analysis. Female. Humans. Leg. Melanoma-Specific Antigens. Microphthalmia-Associated Transcription Factor / analysis. Middle Aged. Neoplasm Proteins / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20139753.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Desmin; 0 / MITF protein, human; 0 / Melanoma-Specific Antigens; 0 / Microphthalmia-Associated Transcription Factor; 0 / Neoplasm Proteins
  •  go-up   go-down


11. Vodicka J, Spidlen V, Klecka J, Simánek V, Safránek J: [Use of the KLS Martin Nd:YAG laser MY 40 13 in lung parenchyma surgery]. Rozhl Chir; 2009 May;88(5):248-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Use of the KLS Martin Nd:YAG laser MY 40 13 in lung parenchyma surgery].
  • INTRODUCTION: Nd:YAG laser MY 40 1.3 has been developed to be employed in lung tumor resections.
  • The laser beam application to the lung parenchyma is continuous and non-contact.
  • AIM: Analysis of our initial experience with the use of the instrument in surgical management of primary and secondary lung tumors.
  • In 12 subjects, lung metastases of malignant tumors were detected, 3 subjects suffered from primary lung carcinoma and two from benign lung lesions.
  • 7 operated subjects had multiple secondary lung tumors in various lobes of a single lung or both lungs, in 5 subjects, the secondary tumors were solitary.
  • All the above surgical procedures were performed under general anesthesia with selective lung ventilation via posterolateral thoracotomy.
  • RESULTS: In the all 12 patients, the lung metastases were radically removed using parenchyma-saving laser metastasectomy.
  • The two benign lesions were managed in a similar way.
  • CONCLUSION: Nd:YAG laser MY 40 1.3 facilitates radical removals of secondary pulmonary neoplasms, in particular of the multiple and deeply located ones, with no need for extensive lung parenchyma resections and with minimum intraoperative morbidity and mortality rates.
  • Furthermore, it can be successfully used in a numer of other surgical procedures, such as management of pleural adhesions, lung biopsies, resections of emphysematous bullae, resections of benign lung tumors, dissections of inerlobal fissures, etc., where the method can fully replace staplers.
  • [MeSH-major] Laser Therapy / instrumentation. Lasers, Solid-State / therapeutic use. Lung Neoplasms / surgery. Pneumonectomy / methods

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19642342.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


12. DeWitt J, Alsatie M, LeBlanc J, McHenry L, Sherman S: Endoscopic ultrasound-guided fine-needle aspiration of left adrenal gland masses. Endoscopy; 2007 Jan;39(1):65-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: Our searches resulted in the identification of a series of 38 consecutive patients who underwent EUS for the evaluation of a lung mass (n = 14), a pancreatic mass (n = 14), obstructive jaundice (n = 1), dysphagia (n = 2), an ampullary adenoma (n = 1), celiac block (n = 1), or a left adrenal gland mass (n = 5).
  • Diagnoses after EUS-FNA (the mean number of passes was 3.6) were: metastatic lung cancer (n = 2), esophageal adenocarcinoma (n = 1), melanoma (n = 1), renal cell carcinoma (n = 1), and pancreatic neuroendocrine tumor (n = 1); primary pheochromocytoma (n = 1); benign adrenal tissue (n = 21); and granulomatous inflammation (n = 1).


13. Rom WN, Goldberg JD, Addrizzo-Harris D, Watson HN, Khilkin M, Greenberg AK, Naidich DP, Crawford B, Eylers E, Liu D, Tan EM: Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers. BMC Cancer; 2010 May 26;10:234
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification of an autoantibody panel to separate lung cancer from smokers and nonsmokers.
  • BACKGROUND: Sera from lung cancer patients contain autoantibodies that react with tumor associated antigens (TAAs) that reflect genetic over-expression, mutation, or other anomalies of cell cycle, growth, signaling, and metabolism pathways.
  • METHODS: We performed immunoassays to detect autoantibodies to ten tumor associated antigens (TAAs) selected on the basis of previous studies showing that they had preferential specificity for certain cancers.
  • Sera examined were from lung cancer patients (22); smokers with ground-glass opacities (GGOs) (46), benign solid nodules (55), or normal CTs (35); and normal non-smokers (36).
  • Logistic regression models based on the antibody biomarker levels among the high risk and lung cancer groups were developed to identify the combinations of biomarkers that predict lung cancer in these cohorts.
  • CONCLUSION: A pattern of autoantibody reactivity to TAAs may distinguish patients with lung cancer versus smokers with normal CTs, stable solid nodules, ground glass opacities, or normal healthy never smokers.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Proc Natl Acad Sci U S A. 2001 Aug 14;98(17):9824-9 [11504947.001]
  • [Cites] Am J Respir Crit Care Med. 2005 Nov 15;172(10):1308-14 [16109979.001]
  • [Cites] Anticancer Res. 2001 Jul-Aug;21(4B):3085-92 [11712815.001]
  • [Cites] J Clin Invest. 2001 Nov;108(10):1411-5 [11714730.001]
  • [Cites] Chest. 2002 May;121(5):1464-7 [12006429.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2298-305 [12114434.001]
  • [Cites] Am J Respir Crit Care Med. 2006 Mar 1;173(5):535-9 [16339918.001]
  • [Cites] N Engl J Med. 2006 Oct 26;355(17):1763-71 [17065637.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3461-7 [17409457.001]
  • [Cites] J Thorac Oncol. 2006 Jul;1(6):513-9 [17409910.001]
  • [Cites] Thorax. 2008 Mar;63(3):228-33 [17932110.001]
  • [Cites] J Clin Oncol. 2008 Nov 1;26(31):5060-6 [18794547.001]
  • [Cites] Clin Immunol. 2001 Aug;100(2):149-56 [11465943.001]
  • [Cites] Oncogene. 2002 Jul 25;21(32):5006-15 [12118381.001]
  • [Cites] Int J Cancer. 2002 Dec 1;102(4):372-8 [12402307.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Feb;12(2):136-43 [12582023.001]
  • [Cites] Lung Cancer. 2003 Mar;39(3):297-301 [12609568.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1652-6 [12670919.001]
  • [Cites] Cancer Detect Prev. 2003;27(4):285-90 [12893076.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Nov 11;100(23):13537-42 [14573703.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5120-6 [14613989.001]
  • [Cites] Int J Cancer. 1982 Oct 15;30(4):403-8 [6292117.001]
  • [Cites] Am J Pathol. 1992 Oct;141(4):881-6 [1415481.001]
  • [Cites] J Clin Invest. 1993 Nov;92(5):2419-26 [8227358.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 May 14;93(10):4529-36 [8643438.001]
  • [Cites] Hepatology. 1997 Jan;25(1):75-80 [8985268.001]
  • [Cites] J Clin Oncol. 1997 Nov;15(11):3363-7 [9363867.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1163-7 [9547328.001]
  • [Cites] J Exp Med. 1998 Apr 20;187(8):1349-54 [9547346.001]
  • [Cites] Clin Cancer Res. 1996 Oct;2(10):1767-75 [9816128.001]
  • [Cites] Ann Neurol. 1999 Feb;45(2):162-7 [9989617.001]
  • [Cites] J Exp Med. 1999 Apr 5;189(7):1101-10 [10190901.001]
  • [Cites] Lancet. 1999 Jul 10;354(9173):99-105 [10408484.001]
  • [Cites] Lung Cancer. 2004 Dec;46(3):313-23 [15541816.001]
  • [Cites] Prostate. 2005 May 15;63(3):252-8 [15538718.001]
  • [Cites] N Engl J Med. 2005 Jun 30;352(26):2714-20 [15987920.001]
  • [Cites] Cancer Res. 2005 Aug 15;65(16):7102-10 [16103059.001]
  • [Cites] BMC Cancer. 2005;5:110 [16117833.001]
  • [Cites] Int J Oncol. 2005 Oct;27(4):1079-85 [16142326.001]
  • [Cites] Cancer Res. 2001 Nov 1;61(21):7908-12 [11691811.001]
  • (PMID = 20504322.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / T32 ES007267; United States / NCRR NIH HHS / RR / M01RR-00096; United States / NCI NIH HHS / CA / U01CA86137; United States / NCI NIH HHS / CA / U01 CA086137-11; United States / NCI NIH HHS / CA / CA086137-11; United States / NIEHS NIH HHS / ES / T32 ES007267-18; United States / NIEHS NIH HHS / ES / ES007267-18; United States / NCI NIH HHS / CA / CA 56956; United States / NCI NIH HHS / CA / U01 CA086137
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Autoantibodies
  • [Other-IDs] NLM/ PMC2885364
  •  go-up   go-down


14. Lu Y, Xie D, Huang W, Gong H, Yu J: 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients. Neoplasma; 2010;57(2):129-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FDG PET/CT in the evaluation of adrenal masses in lung cancer patients.
  • The aim of this study was to assess the usefulness of integrated (18)F-FDG PET/CT in differentiating benign from metastatic malignant adrenal masses in patients with lung cancer.
  • One hundred and ten adrenal masses (size range, 0.5 - 6.3 cm, mean size, 1.9 cm) were evaluated retrospectively in 87 lung cancer patients.
  • PET/CT findings were negative in 33 adrenal masses, of which 31 eventually proved to be benign.
  • Integrated (18)F-FDG PET-CT is an accurate, noninvasive technique for differentiating benign from metastatic adrenal lesions detected on CT or MRI in patients with lung cancer.
  • It allows early detection and accurate localization of adrenal lesions and differentiation of metastatic nodules from benign lesions, thereby facilitating treatment planning.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals. Tomography, X-Ray Computed
  • [MeSH-minor] Adenocarcinoma / radiography. Adenocarcinoma / radionuclide imaging. Adenocarcinoma / secondary. Adult. Aged. Carcinoma, Large Cell / radiography. Carcinoma, Large Cell / radionuclide imaging. Carcinoma, Large Cell / secondary. Carcinoma, Squamous Cell / radiography. Carcinoma, Squamous Cell / radionuclide imaging. Carcinoma, Squamous Cell / secondary. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Small Cell Lung Carcinoma / radiography. Small Cell Lung Carcinoma / radionuclide imaging. Small Cell Lung Carcinoma / secondary


15. Schröder FH: Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC). Can J Urol; 2005 Feb;12 Suppl 1:2-6; discussion 92-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The ERSPC together with the prostate cancer arm of the Prostate, Lung, Colon and Ovary (PLCO) screening trial of the National Cancer Institute in the United States are set to show or exclude an effect of screening on prostate cancer mortality.
  • Present screening needs to be more "selective" for cases that have aggressive patterns and are likely to lead to clinical diagnosis of prostate cancer and/or death.
  • This may be compatible with the observation that tumor volumes in second round screening are smaller, and larger tumors are harvested.
  • Tumor volume becomes a negative predictor in round 2, indicating that a large proportion of elevated PSA values are caused by benign prostatic hyperplasia (BPH) rather than by prostate cancer.
  • [MeSH-major] Mass Screening / standards. Prostate-Specific Antigen / blood. Prostatic Neoplasms / diagnosis
  • [MeSH-minor] Age Distribution. Aged. Europe / epidemiology. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Prognosis. Randomized Controlled Trials as Topic. Risk Assessment. Survival Rate. Time Factors


16. Isidori AM, Lenzi A: Ectopic ACTH syndrome. Arq Bras Endocrinol Metabol; 2007 Nov;51(8):1217-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ectopic adrenocorticotropic secretion (EAS) is responsible for 12-17% of cases of Cushing's syndrome (CS) and covers a range of tumours, from undetectable benign lesions to widespread metastases.
  • EAS requires a complete workup that includes the establishment of endogenous CS, diagnosis of adrenocorticotropic hormone (ACTH) dependency, localization of the source of ACTH secretion and rapid biochemical control of hypercortisolaemia.
  • In addition to small cell lung carcinoma, the most common causes of ectopic EAS are bronchial carcinoids, thymic tumours, islet cell tumour of the pancreas, medullary thyroid carcinomas, and phaeochromocytomas.
  • [MeSH-major] ACTH Syndrome, Ectopic / diagnosis
  • [MeSH-minor] Abdominal Neoplasms / complications. Abdominal Neoplasms / secretion. Adrenocorticotropic Hormone / blood. Biomarkers / blood. Carcinoid Tumor / complications. Carcinoid Tumor / secretion. Corticotropin-Releasing Hormone. Cushing Syndrome / diagnosis. Diagnosis, Differential. Humans. Hydrocortisone / blood. Petrosal Sinus Sampling. Thoracic Neoplasms / complications. Thoracic Neoplasms / secretion. Tomography, X-Ray Computed

  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • Hazardous Substances Data Bank. Corticotropin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18209859.001).
  • [ISSN] 0004-2730
  • [Journal-full-title] Arquivos brasileiros de endocrinologia e metabologia
  • [ISO-abbreviation] Arq Bras Endocrinol Metabol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Biomarkers; 9002-60-2 / Adrenocorticotropic Hormone; 9015-71-8 / Corticotropin-Releasing Hormone; WI4X0X7BPJ / Hydrocortisone
  • [Number-of-references] 53
  •  go-up   go-down


17. Iavazzo C, Vorgias G, Sampanis D, Mavromatis I, Manikis P, Katsoulis M: Meig's or Pseudomeig's syndrome? Bratisl Lek Listy; 2007;108(3):158-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The triad of ascites, hydrothorax in association with a benign ovarian tumor is defined as Meig's syndrome.
  • Clinical and ultrasonographic findings revealed extended palpable pelvic mass originating from the ovaries and ascites as well as hydrothorax of the left lung by chest radiography.
  • [MeSH-major] Meigs Syndrome / diagnosis
  • [MeSH-minor] Adenocarcinoma / complications. Adenocarcinoma / diagnosis. Adenocarcinoma / secondary. Adenocarcinoma / surgery. Female. Humans. Middle Aged. Ovarian Neoplasms / complications. Ovarian Neoplasms / diagnosis. Ovarian Neoplasms / pathology. Ovarian Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17682545.001).
  • [ISSN] 0006-9248
  • [Journal-full-title] Bratislavské lekárske listy
  • [ISO-abbreviation] Bratisl Lek Listy
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Slovakia
  •  go-up   go-down


18. Hanaoka T, Sone S, Ino H, Takayama F, Sato T, Kanaya H, Ogata H: Subcentimeter large cell neuroendocrine carcinoma of the lung. J Thorac Imaging; 2005 Nov;20(4):288-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcentimeter large cell neuroendocrine carcinoma of the lung.
  • To our knowledge, no report exists of a subcentimeter size large cell neuroendocrine carcinoma (LCNEC) of the lung.
  • A 75-year-old man participating in a low-dose CT screening program for lung cancer was found incidentally to have a partly-solid nodule in the right upper lung.
  • The final diagnosis was stage IA-LCNEC.
  • The estimated volume doubling time of the tumor was 30.1 days.
  • These aggressive tumors may rarely have doubling times that overlap with benign processes.
  • [MeSH-major] Carcinoma, Large Cell / radiography. Carcinoma, Neuroendocrine / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Aged. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Thoracic Surgery, Video-Assisted

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16282907.001).
  • [ISSN] 0883-5993
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Targowski T, Jahnz-Rózyk K, Szkoda T, Płusa T, From S: Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival. Lung Cancer; 2008 Jul;61(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase activity in transthoracic fine-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival.
  • PURPOSE: Evaluation of the relationship between telomerase activity in transthoracic fine-needle biopsy (TFNB) aspirates collected from peripheral non-small cell lung cancer (NSCLC), cancer advancement, risk of death and free of cancer recurrence survival.
  • MATERIAL AND METHODS: The study group consisted of 93 patients with peripheral infiltration of the lung.
  • RESULTS: A benign lesion of the lung was recognised in 14 cases.
  • Nobody with benign infiltration had a detectable level of telomerase in lung infiltration.
  • Increased telomerase activity was observed in 56 (70.9%) patients with lung cancer.
  • [MeSH-major] Biomarkers, Tumor / analysis. Carcinoma, Non-Small-Cell Lung / enzymology. Lung Neoplasms / enzymology. Telomerase / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18063440.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


20. Mei X, Sun Y, Xu M, Ma D, Wei D, Tian J, Ren Z: [Research of loss of heterozygaity on chromosome 3p in non-small cell lung cancer.]. Zhongguo Fei Ai Za Zhi; 2008 Aug 20;11(4):534-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Research of loss of heterozygaity on chromosome 3p in non-small cell lung cancer.].
  • BACKGROUND: It has been proven that allelic loss of chromosome region 3p occurs early and frequently in non-small-cell lung cancer, and numerous tumor suppressor genes at this locus may be targets of inactivation.
  • METHODS: A total of 32 NSCLC samples and 8 tissues of the pulmonary benign disease have been analyzed by fluorescent quantitative PCR.
  • RESULTS: There were 25 of the 32 cases (78.125%) with NSCLC tumor had LOH on 3p .
  • LOH detection in the nucleated cells in peripheral blood was correlation with the tumor tissues and the combined detection is better than single ones.
  • The 3p LOH detection of the tumor tissue and the nucleated cell in peripheral blood is beneficial to the diagnosis of NSCLC.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20735964.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Joshi SC, Pant I, Hamzah F, Kumar G, Shukla AN: Integrated positron emission tomography/computed tomography fusion imaging: an emerging gold standard in lung cancer. Indian J Cancer; 2008 Oct-Dec;45(4):137-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrated positron emission tomography/computed tomography fusion imaging: an emerging gold standard in lung cancer.
  • Positron emission tomography (PET) has emerged as an important diagnostic tool in the management of lung cancers.
  • Although PET is sensitive in detection of lung cancer, but FDG (2-deoxy-2- 18 fluro-D-glucose) is not tumor specific and may accumulate in a variety of nonmalignant conditions occasionally giving false positive result.
  • Addition of CT to PET improves specificity foremost, but also sensitivity in tumor imaging.
  • PET/CT fusion images are useful in differentiating between malignant and benign disease, fibrosis and recurrence, staging and in changing patient management to more appropriate therapy.
  • With analysis and discussion it appears that PET/ CT fusion images have the potential to dramatically improve our ability to manage the patients with lung cancer and is contributing to our understanding of cancer cell biology and in development of new therapies.
  • [MeSH-major] Lung Neoplasms / radiography. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Carcinoma, Non-Small-Cell Lung / radiography. Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Humans

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19112200.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Number-of-references] 28
  •  go-up   go-down


22. Liu XQ, Ren HX, Wu ZP: [Detecting MUC-1 mRNA for diagnosing peripheral blood micro-metastasis in non-small cell lung cancer patients]. Ai Zheng; 2008 Dec;27(12):1267-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Detecting MUC-1 mRNA for diagnosing peripheral blood micro-metastasis in non-small cell lung cancer patients].
  • BACKGROUND & OBJECTIVE: Mucins, including MUC-1, are generally considered to be products of epithelial tissues and epithelial tumors.
  • This study was to explore the feasibility of MUC-1 mRNA as a molecular marker in detecting peripheral blood micro-metastasis in patients with non-small cell lung cancer (NSCLC).
  • METHODS: Nested reverse transcription-polymerase chain reaction (RT-PCR) was used to detect MUC-1 gene expression in peripheral blood samples from 60 patients with NSCLC, 15 patients with benign pulmonary disease, and 20 healthy subjects.
  • RESULTS: The positive rates of MUC-1 mRNA were 80.0% in NSCLC group, 60.0% in benign pulmonary disease group, and 65.0% in healthy group.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Mucin-1 / blood. Neoplastic Cells, Circulating / metabolism
  • [MeSH-minor] Biomarkers, Tumor. Cell Line, Tumor. Humans. Lung Diseases / blood. Polymerase Chain Reaction. RNA, Messenger / blood


23. Cordeiro SZ, Cordeiro Pde B, Sousa AM, Lannes DC, Pierro GS: Giant cell tumor of the rib occupying the entire hemithorax. J Bras Pneumol; 2008 Mar;34(3):185-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant cell tumor of the rib occupying the entire hemithorax.
  • The authors report the case of a 28-year-old female patient with a giant cell tumor originating from the rib.
  • The tumor, measuring 25 x 17 cm, occupied the entire hemithorax and caused atelectasis of the left lung.
  • This tumor was a benign mesenchymal neoplasm, which rarely affects the ribs.
  • A thoracotomy involving en bloc resection of the chest wall and tumor was performed.
  • Despite the large dimensions of the tumor, complete resection was possible, and lung function was restored.
  • [MeSH-major] Bone Neoplasms / diagnosis. Giant Cell Tumor of Bone / diagnosis. Ribs

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18392468.001).
  • [ISSN] 1806-3756
  • [Journal-full-title] Jornal brasileiro de pneumologia : publicaça̋o oficial da Sociedade Brasileira de Pneumologia e Tisilogia
  • [ISO-abbreviation] J Bras Pneumol
  • [Language] eng; por
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


24. Hirata T, Otani T, Minamiguchi S: Clear cell tumor of the lung. Int J Clin Oncol; 2006 Dec;11(6):475-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clear cell tumor of the lung.
  • Clear cell tumor of the lung is a rare benign tumor.
  • We report herein a case of clear cell tumor of the lung.
  • Investigation with abdominal CT scans showed no evidence of renal disease, and the tumor was diagnosed as clear cell tumor of the lung.
  • [MeSH-major] Adenocarcinoma, Clear Cell / diagnosis. Lung Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Cytol. 1989 Jul-Aug;33(4):511-5 [2750440.001]
  • [Cites] Eur J Cardiothorac Surg. 2004 Apr;25(4):652-4 [15037292.001]
  • [Cites] Chirurg. 2003 Jul;74(7):683-6 [12883798.001]
  • [Cites] Am J Surg Pathol. 1997 Oct;21(10):1242-7 [9331299.001]
  • [Cites] Am J Surg Pathol. 1991 Feb;15(2):199-202 [2025321.001]
  • [Cites] Arch Pathol Lab Med. 1991 Oct;115(10):1034-8 [1898230.001]
  • [Cites] Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Jul;33(7):765-70 [7564005.001]
  • [Cites] Am J Surg Pathol. 1991 Jul;15(7):644-53 [1711793.001]
  • [Cites] Surg Today. 1998;28(9):985-7 [9744416.001]
  • [Cites] Yale J Biol Med. 1971 Feb-Apr;43(4-5):213-22 [5578741.001]
  • [Cites] AJR Am J Roentgenol. 1996 Mar;166(3):730-1 [8623676.001]
  • [Cites] Radiology. 1978 Dec;129(3):595-6 [725030.001]
  • (PMID = 17180518.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


25. Dim DC, Nugent SL, Peng HQ: Ganglioneuroma presenting as a paraesophageal mass lesion diagnosed by endoscopic ultrasound-guided fine needle aspiration cytology: a case report. Acta Cytol; 2010 May-Jun;54(3):321-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Endoscopic ultrasound-guided fine needle aspiration is a well-established modality in detection and diagnosis of mediastinal lesions.
  • Ganglioneuroma is a benign, rare, soft tissue neoplasm arising from sympathetic ganglion cells, and complete surgical resection is considered to be curative.
  • Ganglioneuroma in a surgical specimen is a straightforward diagnosis; however, due to the infrequent occurrence of this entity, diagnosis by fine needle aspiration is more challenging.
  • A 75-year-old man with a history of adenocarcinoma of the lung was noted to have a mediastinal mass on chest computed tomography.
  • [MeSH-major] Ganglioneuroma / diagnosis. Mediastinal Neoplasms / pathology. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Biomarkers, Tumor / metabolism. Biopsy, Fine-Needle. Diagnosis, Differential. Endosonography. Esophagus / pathology. Humans. Male. S100 Proteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20518419.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / S100 Proteins
  •  go-up   go-down


26. Jin FG, Fu EQ, Xie YH, Li WP, Nan YD, Liu W, Sun RL: [The application of combined interventional procedures for the management of intractable central airway stenosis]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jan;33(1):21-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Among them, two or more procedures were combined to manage complicated airway stenosis according to stenosis causes, types, position, degree and duration, or functions of distal lung tissue and airway.
  • Among 23 cases benign disease, including 4 benign tumor, 15 tuberculosis and 4 other granulomatosis, 5 cases with various degrees of restenosis needed further interventional therapy after 3 months of follow up and effective rate was 78.3% (18/23).
  • Patients with malignant tumor were not followed up for long term.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20368019.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G: Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res; 2008;27:34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical expression of the glucose transporters Glut-1 and Glut-3 in human malignant melanomas and benign melanocytic lesions.
  • This study was undertaken to assess the differential expression of Glut-1 and Glut-3 by benign and malignant melanocytic lesions.
  • RESULTS: We observed immunoreactivity for Glut-1 in all melanocytic nevi, 9 of the 12 Spitz nevi and in 9 of the 20 malignant melanomas, whereas Glut-3 was expressed in all the melanocytic lesions, both benign and malignant.
  • Glut-1 was present in the majority of benign nevi, whereas its expression was downregulated in 55% of malignant melanomas.
  • Our results suggest that glucose transporter Glut-1 expression can significantly discriminate between human malignant melanoma and benign melanocytic nevi, and support the idea that additional mechanisms other than Glut-1 may contribute to glucose uptake in melanomas.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Humans. Immunohistochemistry

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Lung Cancer. 2007 Jan;55(1):79-87 [17046099.001]
  • [Cites] Oncologist. 2002;7(4):271-8 [12185291.001]
  • [Cites] Pathol Oncol Res. 2007;13(1):15-20 [17387384.001]
  • [Cites] Melanoma Res. 2007 Jun;17(3):147-54 [17505260.001]
  • [Cites] J Exp Clin Cancer Res. 2007 Mar;26(1):71-6 [17550134.001]
  • [Cites] Oral Oncol. 2007 Sep;43(8):796-803 [17207657.001]
  • [Cites] Urology. 2000 Mar;55(3):448-52 [10699635.001]
  • [Cites] Cancer Res. 2000 Nov 1;60(21):6189-95 [11085544.001]
  • [Cites] Eur J Cancer. 2001 Jan;37(2):204-9 [11166147.001]
  • [Cites] Physiol Genomics. 2001 Feb 7;5(1):21-33 [11161003.001]
  • [Cites] Int J Cancer. 2003 Mar 10;104(1):85-91 [12532423.001]
  • [Cites] J Nucl Med. 2004 Jan;45(1):22-9 [14734665.001]
  • [Cites] Melanoma Res. 2004 Apr;14(2):141-5 [15057045.001]
  • [Cites] Surgery. 2004 Sep;136(3):548-56 [15349101.001]
  • [Cites] J Biol Chem. 1990 Aug 15;265(23):13578-83 [2380175.001]
  • [Cites] Cancer. 1993 Nov 15;72(10):2979-85 [8221565.001]
  • [Cites] Annu Rev Nutr. 1996;16:235-56 [8839927.001]
  • [Cites] J Nucl Med. 1997 Sep;38(9):1337-44 [9293783.001]
  • [Cites] J Am Acad Dermatol. 1997 Oct;37(4):575-7 [9344196.001]
  • [Cites] Mod Pathol. 1998 May;11(5):437-43 [9619596.001]
  • [Cites] Pathol Oncol Res. 1998;4(2):115-20 [9654596.001]
  • [Cites] J Nucl Med. 1999 Feb;40(2):339-46 [10025844.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1508-15 [10334538.001]
  • [Cites] Oncol Rep. 2005 Dec;14(6):1499-504 [16273245.001]
  • [Cites] Hum Pathol. 2006 Feb;37(2):190-7 [16426919.001]
  • [Cites] Hum Mol Genet. 2006 Apr 1;15(7):1169-79 [16497725.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2006 Jun;33(6):683-91 [16506050.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2006 Jun;14(2):187-92 [16785788.001]
  • [Cites] Hum Pathol. 2006 Aug;37(8):1085-92 [16867872.001]
  • [Cites] Dig Dis Sci. 2006 Dec;51(12):2198-205 [17080242.001]
  • [Cites] Clin Cancer Res. 2001 Apr;7(4):928-34 [11309343.001]
  • [Cites] Melanoma Res. 2002 Feb;12(1):35-43 [11828256.001]
  • [Cites] J Natl Cancer Inst. 2002 Jul 17;94(14):1080-91 [12122099.001]
  • [Cites] Mod Pathol. 2007 Feb;20(2):215-20 [17192790.001]
  • (PMID = 18764953.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glucose Transporter Type 1; 0 / Glucose Transporter Type 3
  • [Other-IDs] NLM/ PMC2553059
  •  go-up   go-down


28. Akata S, Yoshimura M, Nishio R, Park J, Saito K, Uchida O, Ohira T, Kato H, Okada S, Kakizaki D: High-resolution computed tomographic findings of small peripherally located squamous cell carcinoma. Clin Imaging; 2008 Jul-Aug;32(4):259-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With the spread of high-resolution computed tomography (HRCT) screening for lung cancer, we are increasingly faced with the need to determine whether certain small lesions are benign or malignant.
  • HRCT findings of all 27 cases were analyzed retrospectively and independently by three radiologists who were unaware of the pathological diagnosis, and decisions were reached by consensus with special attention to 10 review points.
  • Tumor margin features included spiculation, notching, irregularity, and ground-glass opacity.
  • HRCT images of peripherally located squamous cell carcinoma suggested that the demonstration of irregularity, surrounding pulmonary emphysema, pleural indentation, and absence of calcification may contribute to the accurate CT diagnosis of small peripheral squamous cell carcinoma.
  • [MeSH-major] Carcinoma, Squamous Cell / radiography. Lung Neoplasms / radiography. Tomography, X-Ray Computed


29. Ruan Z, Zheng J, Huang H, Zhang W, Zhao J: [Clinical evaluation of ¹⁸F-FDG-SPECT/CT imaging in diagnosis and staging of patients with suspected lung cancer]. Zhongguo Fei Ai Za Zhi; 2005 Apr 20;8(2):120-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical evaluation of ¹⁸F-FDG-SPECT/CT imaging in diagnosis and staging of patients with suspected lung cancer].
  • BACKGROUND: Correct diagnosis is very important to patients with suspected lung cancer.
  • According to the higher ¹⁸F-FDG intake of tumor tissues much more than normal tissues, this study evaluates the clinical value of ¹⁸F-FDG dual-head coincidence SPECT/CT in diagnosis of lung cancer.
  • METHODS: Sixty-one patients with lung mass underwent ¹⁸F-FDG dual-head coincidence SPECT/CT imaging and thoracic CT imaging before operation.
  • These imageological results were compared with histological examination of lung mass.
  • RESULTS: The sensitivity, specificity and accuracy of ¹⁸F-FDG-SPECT/CT in differentiating malignant and benign lesions were 82%, 87%, 84%, respectively.
  • CONCLUSIONS: Combined functional-anatomical image of ¹⁸F-FDG-SPECT/CT has potential to improve staging and localizing procedures of lung cancer.
  • It is an excellent modality in diagnosis and differential diagnosis of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189179.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


30. Hayashi T, Tagawa T, Ashizawa K, Abe K, Kinoshita N, Tsutsui S, Anami M, Nagayasu T: Contrast-enhanced dynamic magnetic resonance imaging of primary pulmonary leiomyosarcoma. Tohoku J Exp Med; 2006 Nov;210(3):263-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest computed tomography (CT) revealed a 55 x 40 mm well-defined mass with smooth margins in the lower lobe of the right lung (S6).
  • However, contrast-enhanced dynamic magnetic resonance imaging (MRI) revealed enhancement of the lesion, which had a clear margin and homogenous consistency, suggesting a benign pulmonary solid tumor.
  • Histopathologically, the tumor consists of spindle cells with ample eosinophilic cytoplasm arranged in an interlacing pattern.
  • Contrast-enhanced dynamic MRI should be carried out to facilitate accurate preoperative diagnosis and selection of the correct surgical plan.
  • [MeSH-major] Contrast Media / pharmacology. Leiomyosarcoma / diagnosis. Leiomyosarcoma / pathology. Lung Neoplasms / diagnosis. Lung Neoplasms / pathology. Magnetic Resonance Imaging / methods
  • [MeSH-minor] Adult. Humans. Immunohistochemistry. Lung / pathology. Male. Radiography, Thoracic / methods. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed / methods

  • Genetic Alliance. consumer health - Leiomyosarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17077604.001).
  • [ISSN] 0040-8727
  • [Journal-full-title] The Tohoku journal of experimental medicine
  • [ISO-abbreviation] Tohoku J. Exp. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


31. Shackelford RE, Bui MM, Coppola D, Hakam A: Over-expression of nicotinamide phosphoribosyltransferase in ovarian cancers. Int J Clin Exp Pathol; 2010;3(5):522-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Using tissue microarray (TMA) and the avidin-biotin complex immunohistochemical technique we examined Nampt expression in 47 samples of benign ovarian tissue and 49 samples of ovarian serous adenoacarcinomas.
  • Our data show that Nampt protein expression is significantly increased in OSAs as compared to benign ovarian tissue (0.49+/-0.12 benign vs. 4.78+/-0.46 malignant; +/-standard error of the mean).
  • [MeSH-major] Biomarkers, Tumor / analysis. Cystadenocarcinoma, Serous / enzymology. Cytokines / biosynthesis. Nicotinamide Phosphoribosyltransferase / biosynthesis. Ovarian Neoplasms / enzymology

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Med Res. 2006 Aug 30;11(8):313-21 [17052966.001]
  • [Cites] Clin Cancer Res. 2006 Sep 1;12(17):5055-63 [16951221.001]
  • [Cites] Mol Cancer. 2007;6:12 [17274819.001]
  • [Cites] Exp Mol Med. 2007 Feb 28;39(1):8-13 [17334224.001]
  • [Cites] Lung Cancer. 2007 Oct;58(1):21-9 [17624472.001]
  • [Cites] Cell. 2007 Sep 21;130(6):1095-107 [17889652.001]
  • [Cites] Genes Dev. 2007 Oct 15;21(20):2644-58 [17938244.001]
  • [Cites] Gynecol Oncol. 2008 Feb;108(2):370-6 [18083218.001]
  • [Cites] Cancer Biol Ther. 2008 May;7(5):663-8 [18728403.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Sep 9;105(36):13421-6 [18755897.001]
  • [Cites] J Clin Oncol. 2008 Nov 10;26(32):5284-93 [18854563.001]
  • [Cites] Oncogene. 2009 Jan 22;28(3):445-60 [18850005.001]
  • [Cites] Trends Endocrinol Metab. 2009 Apr;20(3):130-8 [19109034.001]
  • [Cites] Pathology. 2009;41(4):366-71 [19404850.001]
  • [Cites] J Gastroenterol. 2009;44(7):685-90 [19430715.001]
  • [Cites] J Biol Chem. 2009 Jul 24;284(30):20408-17 [19478080.001]
  • [Cites] Nat Rev Cancer. 2009 Nov;9(11):798-809 [19851315.001]
  • [Cites] Oncogene. 2010 Mar 25;29(12):1741-52 [20062075.001]
  • [Cites] FEBS Lett. 1999 Dec 10;463(1-2):77-82 [10601642.001]
  • [Cites] Br J Cancer. 2000 Feb;82(3):621-8 [10682675.001]
  • [Cites] Oncogene. 2000 May 15;19(21):2474-88 [10851046.001]
  • [Cites] Int J Cancer. 2002 Sep 10;101(2):118-27 [12209988.001]
  • [Cites] Int J Gynecol Cancer. 2002 Nov-Dec;12(6):691-703 [12445245.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7436-42 [14612543.001]
  • [Cites] J Biol Chem. 2004 Dec 3;279(49):50754-63 [15381699.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1053-65 [15558012.001]
  • [Cites] Arthritis Rheum. 2006 Jul;54(7):2084-95 [16802343.001]
  • [Cites] Cancer. 2006 Dec 1;107(11):2730-40 [17063503.001]
  • (PMID = 20606733.001).
  • [ISSN] 1936-2625
  • [Journal-full-title] International journal of clinical and experimental pathology
  • [ISO-abbreviation] Int J Clin Exp Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; EC 2.4.2.12 / Nicotinamide Phosphoribosyltransferase; EC 2.4.2.12 / nicotinamide phosphoribosyltransferase, human
  • [Other-IDs] NLM/ PMC2897104
  • [Keywords] NOTNLM ; Interleukin-6 / Nicotinamide phosphoribosyltransferase / Stat3 / nicotinamide adenine dinucleotide / ovarian cancer / serous adenocarcinoma
  •  go-up   go-down


32. Zheng SE, Yao Y, Dong Y, Lin F, Zhao H, Shen Z, Sun YJ, Tang LN: Down-regulation of ribosomal protein L7A in human osteosarcoma. J Cancer Res Clin Oncol; 2009 Aug;135(8):1025-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Ribosomal protein L7A mRNA expression was quantified by real-time reverse transcription (RT)-polymerase chain reaction (PCR) in 47 specimens from osteosarcoma, 8 from normal bone tissues and 12 from benign bone lesion tissues.
  • The immunoblotting pattern of RPL7A was also analyzed in 20 osteosarcomas, 8 normal bone and 8 benign bone tissues.
  • RESULTS: Ribosomal protein L7A mRNA expression in osteosarcoma samples was significantly down-regulated compared with that in samples from normal bone (P < 0.001) and benign bone lesion tissues (P < 0.001).
  • Low expression of RPL7A mRNA was significantly associated with increased serum level of alkaline phosphatase (ALP, P = 0.008), but was not correlated with other clinicopathological parameters including sex, age, serum lactate dehydrogenase (LDH), tumor location, histological type, histological grading, lung metastasis and overall survival.
  • Interestingly, survival analysis suggested low RPL7A mRNA expression was a significant poor prognostic indicator for overall survival in patients with high grade lesion developed lung metastasis at the time of diagnosis of the primary osteosarcoma (P < 0.05).
  • On western blot, reduced expression of RPL7A protein was observed in osteosarcoma samples (n = 20) compared with normal bone (n = 8) (P < 0.001) and benign bone tissues (n = 8) (P < 0.001).
  • Loss of RPL7A expression may be associated with poor survival of osteosarcoma patients with lung metastasis.
  • [MeSH-minor] Adolescent. Adult. Cell Line, Tumor. Child. Child, Preschool. Female. Humans. Male. Middle Aged. RNA, Messenger / metabolism

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 1992 May 1;52(9):2419-23 [1568211.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Aug;145(1):1-30 [12885459.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3042-8 [8187094.001]
  • [Cites] Mol Cell Endocrinol. 1999 May 25;151(1-2):65-77 [10411321.001]
  • [Cites] Breast Cancer Res Treat. 2001 Sep;69(1):29-38 [11759826.001]
  • [Cites] Int J Oncol. 2000 Apr;16(4):757-62 [10717245.001]
  • [Cites] Am J Hum Genet. 2006 Dec;79(6):1110-8 [17186470.001]
  • [Cites] Cancer Chemother Pharmacol. 2000;45(2):93-102 [10663623.001]
  • [Cites] Chest Surg Clin N Am. 1998 Feb;8(1):77-95 [9515174.001]
  • [Cites] Cancer Cell. 2003 Jun;3(6):537-49 [12842083.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Oct 10;92(21):9525-9 [7568167.001]
  • [Cites] Tumori. 2004 Sep-Oct;90(5):478-84 [15656333.001]
  • [Cites] Nat Genet. 1999 Feb;21(2):169-75 [9988267.001]
  • [Cites] Medicine (Baltimore). 1996 Mar;75(2):77-8 [8606629.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):27-32 [9724090.001]
  • [Cites] Clin Orthop Relat Res. 1996 Mar;(324):86-97 [8595781.001]
  • [Cites] PLoS Biol. 2004 May;2(5):E139 [15138505.001]
  • [Cites] Genome Res. 1998 May;8(5):419-21 [9582186.001]
  • [Cites] Chin J Physiol. 2003 Dec 31;46(4):181-6 [15074839.001]
  • [Cites] Cell Biochem Funct. 2008 Jan-Feb;26(1):107-10 [17437320.001]
  • [Cites] Cancer Genet Cytogenet. 1997 May;95(1):74-87 [9140456.001]
  • [Cites] Immunol Cell Biol. 1999 Jun;77(3):197-205 [10361251.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):145-52 [12645653.001]
  • [Cites] Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4237-43 [16857797.001]
  • [Cites] Pathol Int. 2000 Nov;50(11):863-71 [11107061.001]
  • [Cites] J Clin Invest. 2005 Jan;115(1):44-55 [15630443.001]
  • [Cites] Trends Biochem Sci. 1996 May;21(5):164-5 [8871397.001]
  • [Cites] Nature. 2005 Jul 28;436(7050):518-24 [16049480.001]
  • [Cites] Nature. 2008 Jan 17;451(7176):335-9 [18202658.001]
  • [Cites] Cancer. 1995 Aug 1;76(3):517-20 [8625135.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Jan;23(1):39-44 [11196268.001]
  • [Cites] Cancer Res. 1990 Dec 15;50(24):7950-4 [2253237.001]
  • [Cites] Hum Mol Genet. 2008 May 1;17(9):1253-63 [18230666.001]
  • [Cites] Cancer Lett. 2000 Aug 11;156(2):191-8 [10880769.001]
  • [Cites] Cancer Genet Cytogenet. 1996 Feb;86(2):136-42 [8603340.001]
  • (PMID = 19125294.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / RPL7A protein, human; 0 / Ribosomal Proteins
  •  go-up   go-down


33. Trahan S, Erickson-Johnson MR, Rodriguez F, Aubry MC, Cheville JC, Myers JL, Oliveira AM: Formation of the 12q14-q15 amplicon precedes the development of a well-differentiated liposarcoma arising from a nonchondroid pulmonary hamartoma. Am J Surg Pathol; 2006 Oct;30(10):1326-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary hamartoma is a benign neoplasm that rarely recurs or undergoes malignant transformation.
  • Herein, we report a 48-year-old woman with a history of an incomplete excised nonchondroid pulmonary hamartoma presenting as an indolent tumor recurrence.
  • Excision of the tumor revealed a well-differentiated liposarcoma arising from the hamartomatous component.
  • These findings suggest that the formation of the 12q14-q15 chromosome amplicon, the characteristic cytogenetic finding of well-differentiated liposarcomas and the structural genomic component of the supernumerary ring and giant rod chromosomes, occurred before the morphologic changes characteristic of these malignant adipose tissue tumors and likely represents a very early molecular event in their development.
  • [MeSH-major] Chromosomes, Human, Pair 12. Gene Amplification. Hamartoma / genetics. Liposarcoma / genetics. Lung Neoplasms / genetics

  • Genetic Alliance. consumer health - Liposarcoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17001166.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Genetic Markers; 0 / HMGA2 Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


34. Adolf K, Wagner L, Bergh A, Stattin P, Ottosen P, Borre M, Birkenkamp-Demtröder K, Orntoft TF, Tørring N: Secretagogin is a new neuroendocrine marker in the human prostate. Prostate; 2007 Apr 1;67(5):472-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Neuroendocrine (NE) differentiation in prostate cancer (PCa), promoted by NE cell secreted products, appears to be associated with tumor progression, poor prognosis, and hormone-refractory disease.
  • We recently reported secretagogin, a hexa-EF-hand Ca(2+) binding protein, as a novel NE marker in carcinoid tumors of the lung and the gastrointestinal tract.
  • METHODS: We analyzed immunoreactivity for secretagogin, chromogranin A (CgA), neuron specific enolase (NSE), and synaptophysin (SYN) in consecutive sections from 87 formalin-fixed paraffin-embedded (FFPE) benign hyperplastic (n = 10) and prostate adenocarcinoma (n = 77) specimens.
  • RESULTS: Secretagogin is cytoplasmic and nuclear expressed in NE and NE differentiated cells, and to a lesser extent in epithelial cells, in the benign prostate and prostate adenocarcinoma cells.
  • Secretagogin stained 82% (46/56) of benign and 71% (48/68) of prostate adenocarcinomas and co-localized with the NE markers CgA and NSE.
  • [MeSH-major] Adenocarcinoma / metabolism. Biomarkers, Tumor / biosynthesis. Calcium-Binding Proteins / biosynthesis. Prostatic Neoplasms / metabolism

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17285592.001).
  • [ISSN] 0270-4137
  • [Journal-full-title] The Prostate
  • [ISO-abbreviation] Prostate
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Calcium-Binding Proteins; 0 / Chromogranin A; 0 / SCGN protein, human; 0 / Secretagogins; 0 / Synaptophysin; EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


35. Tan S, Cheng Z, Ma Y, Tan S, Yin Z, Hu W, Yu F: [LUNX mRNA in regional lymph nodes of non-small cell lung cancer patients by RT-PCR and its clinical significance]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Dec;35(12):1236-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [LUNX mRNA in regional lymph nodes of non-small cell lung cancer patients by RT-PCR and its clinical significance].
  • OBJECTIVE: To evaluate the detection of humen-lung-specific X protein (LUNX) gene in micrometastases of patients with non-small cell lung cancer.
  • METHODS: The expression of LUNX gene in tumor tissue, lung and lymph nodes was detected by reverse transcriptase-polymerase chain reaction(RT-PCR) both in 43 non-small-cell lung cancer patients (the experimental group) and 15 lung benign patients (the control group).
  • LUNX mRNA expression in clinic pathology,stage of cancer cell differentiation, clinic stage, age, sex, smoking history, and 4 lung cancer blood markers (CEA,CA125,NSE, and CYFRA211) were evaluated.
  • The LUNX mRNA positive in the lymph nodes was closely related to the pathological type, cancer cell differentiation and clinic stage(r=0.660,0.500,0.460; P=0.011,0.017,0.022, all P<0.05), while not closely related to age, sex, smoking history and 4 lung cancer blood markers (CEA,CA125, NSE, and CYFRA211) (r=0.111, 0.135,0.083,0.354; P=0.739,0.714,0.773,0.125,all P>0.05).
  • The expression of LUNX gene mRNA in the lymph nodes is a valuable index for the detection of micrometastases in patients with non-small cell lung cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Glycoproteins / metabolism. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Phosphoproteins / metabolism

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21200090.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BPIFA1 protein, human; 0 / Biomarkers, Tumor; 0 / Glycoproteins; 0 / Phosphoproteins; 0 / RNA, Messenger
  •  go-up   go-down


36. Liu Z, Xu S, Xiao N, Song C, Zhang H, Li F: [Overexpression of IL-8 and MMP-9 confer high malignant phenotype in patients with non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi; 2010 Aug;13(8):795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Overexpression of IL-8 and MMP-9 confer high malignant phenotype in patients with non-small cell lung cancer].
  • BACKGROUND AND OBJECTIVE: IL-8 (interleukin-8) has been identified as a chemotactic factor, but recent found that IL-8 and matrix metalloproteinase-9 (MMP-9) are important cytokines which are closely related to the growth and metastasis of tumor.
  • The aim of this study is to explore the relationship between IL-8, MMP-9 expressions and clinical pathological features of non-small cell lung cancer (NSCLC) patients and evaluate the diagnostic potential of IL-8, MMP-9 as tumor markers.
  • METHODS: The serum levels of IL-8 and MMP-9 were detected by enzyme-linked immunosorbentassay (ELISA) in 141 NSCLC patients, 40 healthy adults and 40 patients with benign pulmonary disease.
  • The expressions of IL-8 and MMP-9 were detected by immunohistochemical method in 95 NSCLC tissues, and 21 benign disease lung tissues, 25 normal lung tissues as control.
  • RESULTS: The level of expression of IL-8 and MMP-9 in serum and tissue of NSCLC was significantly higher than that of healthy and benign respiratory disease, and the expression was gradually increased with the upgrade of clinicopathological stage.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Non-Small-Cell Lung / pathology. Gene Expression Regulation, Neoplastic. Interleukin-8 / genetics. Lung Neoplasms / genetics. Lung Neoplasms / pathology. Matrix Metalloproteinase 9 / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20704821.001).
  • [ISSN] 1999-6187
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Interleukin-8; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


37. Jin MS, Ha HJ, Baek HJ, Lee JC, Koh JS: Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report. Acta Cytol; 2008 May-Jun;52(3):357-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomyomatous hamartoma of lung mimicking benign mucinous tumor in fine needle aspiration biopsy: a case report.
  • Cytologic features of adenomyomatous hamartoma, a special variant of PH, are not documented in the literature and are confused with epithelial neoplasm in the case of sparse stromal cellularity.
  • Fine needle aspiration biopsy (FNAB) revealed numerous mucinous epithelial cells presenting predominantly in cohesive cellular sheets that suggested benign mucinous epithelial lesion.
  • The patient underwent surgery for the tumor, and it was histologically proven to be an adenomyomatous hamartoma.
  • This case demonstrates the wide spectrum of PH in FNAB and led us to consider PH as a differential diagnosis despite lack of chondromyxoid stromal components.
  • [MeSH-major] Biopsy, Fine-Needle. Hamartoma / diagnosis. Lung Neoplasms / diagnosis
  • [MeSH-minor] Carcinoma, Mucoepidermoid / diagnosis. Carcinoma, Mucoepidermoid / pathology. Diagnosis, Differential. Humans. Male. Middle Aged. Thoracic Surgery, Video-Assisted. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540306.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


38. Liu J, He JX, Cai CJ, Chen HZ, Wei B, Shao WL, Li SB: [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura]. Zhonghua Jie He He Hu Xi Za Zhi; 2010 Jun;33(6):432-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The analysis on the misdiagnosis of solitary fibrous tumor of the pleura].
  • OBJECTIVE: To report the characteristics of solitary fibrous tumor of the pleura (SFTP), and to analyze the factors associated with the misdiagnosis of this disease.
  • RESULTS: The preoperative diagnosis was pleural mesothelioma in 7 cases, neurogenic tumor in 6, lung cancer in 4, SFTP in 2, hilar lymph node tuberculosis in 1 and inflammatory granuloma in 1 case.
  • All the cases underwent radical resection, and postoperative pathology and immunohistochemical study were performed, and the diagnosis of benign solitary fibrous tumor of the pleura was confirmed.
  • CONCLUSION: The recognition of the clinical characteristics of pleural solitary fibrous tumor is essential for improving the diagnosis of this uncommon disease.
  • [MeSH-major] Diagnostic Errors. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20979815.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


39. Gerszten PC, Novotny J Jr, Quader M, Dewald VC, Flickinger JC: Prospective evaluation of a dedicated spine radiosurgery program using the Elekta Synergy S system. J Neurosurg; 2010 Dec;113 Suppl:236-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common histological types for the metastatic lesions (136 cases total) were breast, lung, sarcomas, and renal cells.
  • The most common benign tumors (30 cases total) included 10 schwannomas, 5 neurofibromas, and 5 meningiomas.
  • RESULTS: The prescribed dose to the gross tumor volume, delivered in a single fraction, ranged from 12 to 20 Gy (mean 16 Gy) in this cohort.
  • The gross tumor volumes ranged from 1.2 to 491.7 cm(3) (mean 39.2 cm(3)).

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121807.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Liang Z, Wang HF, Wu AZ, Cai JH: [Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Nov;30(11):2516-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical value of multi-tumor markers protein biochip in the diagnosis of pulmonary carcinoma].
  • OBJECTIVE: To assess the value of multi-tumor markers protein biochip in the diagnosis and therapy of pulmonary carcinoma.
  • METHODS: Twelve tumor markers (CA199, NSE, CEA, CA242, Ferrtin, β-HCG, AFP, f-PSA, PSA, CA125, HGH, and CA153) were detected using protein chip in 308 patients with pulmonary carcinoma, 218 with benign lung lesions and 250 healthy subjects.
  • RESULTS: The positivity rate was 72.4% in pulmonary carcinoma cases, obviously higher than that in the benign cases (22.0%, P<0.01) and healthy subjects (5.6%, P<0.01).
  • CONCLUSION: Protein biochip containing multiple tumor markers provides valuable assistance in the diagnosis and therapeutic effect monitoring of pulmonary carcinoma.
  • [MeSH-major] Adenocarcinoma / diagnosis. Biomarkers, Tumor / analysis. Lung Neoplasms / diagnosis. Protein Array Analysis

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21097421.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


41. Nowak AK, Armato SG 3rd, Ceresoli GL, Yildirim H, Francis RJ: Imaging in pleural mesothelioma: a review of imaging research presented at the 9th International Meeting of the International Mesothelioma Interest Group. Lung Cancer; 2010 Oct;70(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of malignant pleural mesothelioma (MPM) poses many challenges for imaging specialists and clinicians due to the anatomic location and unique growth pattern of this tumor.
  • Nevertheless, imaging in MPM plays a critical role in diagnosis, prognostication, prediction or measurement of response to therapy, and monitoring of disease recurrence after aggressive surgical management.
  • These uses included FDG-PET imaging at the point of diagnosis, in prognostication, and in the assessment of response to chemotherapy.
  • At diagnosis, FDG-PET parameters had a high sensitivity and specificity for differentiation of benign from malignant pleural disease.
  • The use of FDG-PET to extract quantitative features from metabolically active tumor volume was shown to be a significant factor in the prediction of patient survival.
  • CT-based assessment of mesothelioma was determined to be inconsistent with spherical-model-based criteria so that changes in tumor area, a presumably more complete assessment of tumor burden, exhibited a 46% concordance rate with changes in linear measurements.
  • [MeSH-major] Diagnostic Imaging / methods. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20541834.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA102085
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Review
  • [Publication-country] Ireland
  •  go-up   go-down


42. Kluijt I, de Jong D, Teertstra HJ, Axwijk PH, Gille JJ, Bell K, van Rens A, van der Velden AW, Middelton L, Horenblas S: Early onset of renal cancer in a family with Birt-Hogg-Dubé syndrome. Clin Genet; 2009 Jun;75(6):537-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Birt-Hogg-Dubé syndrome is a hereditary syndrome characterized by benign disease of skin and lungs and a risk of malignant renal tumors.
  • [MeSH-major] Family. Kidney Neoplasms / diagnosis. Kidney Neoplasms / genetics
  • [MeSH-minor] Adult. Age of Onset. Aged. Base Sequence. Carcinoma, Papillary / diagnosis. Carcinoma, Papillary / epidemiology. Carcinoma, Papillary / genetics. DNA / analysis. Female. Humans. Lung Diseases / diagnosis. Lung Diseases / genetics. Male. Middle Aged. Molecular Sequence Data. Pedigree. Pneumothorax / diagnosis. Pneumothorax / genetics. Proto-Oncogene Proteins / genetics. Sequence Deletion. Skin Abnormalities / diagnosis. Skin Abnormalities / genetics. Syndrome. Tumor Suppressor Proteins / genetics


43. Mendes RA, Carvalho JF, Waal Iv: An overview on the expression of cyclooxygenase-2 in tumors of the head and neck. Oral Oncol; 2009 Oct;45(10):e124-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An overview on the expression of cyclooxygenase-2 in tumors of the head and neck.
  • Cyclooxygenase-2 (COX-2) levels are increased in various tumors, particularly those involving the esophagus, stomach, breast, pancreas, lung, colon, skin, urinary bladder, prostate and head and neck.
  • Thus, the literature shows increasing evidence that overexpression of the COX-2 plays an important role in tumor growth and spread of tumors by interfering with different biological processes such as cell proliferation, cellular adhesion, immune surveillance, apoptosis, and angiogenesis.
  • Furthermore, the expression of COX-2 might shed some light over the physiopathology and clinical behavior of tumors of the head and neck, including benign odontogenic neoplasms of the jaws with an aggressive behavior, such as keratocystic odontogenic tumors (KCOT).
  • Ultimately, the research of molecular markers associated with the biological behavior of tumors will help to understand the underlying molecular mechanisms and to predict the clinical outcome, leading to the development of new therapeutic applications, such as molecular-targeted treatment and patient tailored therapy.
  • [MeSH-major] Cyclooxygenase 2 / metabolism. Head and Neck Neoplasms / metabolism. Neoplasm Proteins / metabolism

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19457709.001).
  • [ISSN] 1879-0593
  • [Journal-full-title] Oral oncology
  • [ISO-abbreviation] Oral Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Prostaglandins; EC 1.14.99.1 / Cyclooxygenase 2
  •  go-up   go-down


44. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A: Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer; 2010 Apr;68(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions.
  • In the case of malignancy the further challenge is to distinguish metastatic tumors from the primary malignant mesothelioma.
  • The first objective of this study was to adapt the commercial FISH-test, UroVysion originally designed for the cytological diagnosis of bladder cancer, to the analysis of cells in effusions.
  • The cytological diagnosis was malignant in 29 cases, inconclusive in 24 cases and benign in 15 cases.
  • The independently verified final diagnoses were mesothelioma in 21 cases, metastatic cancer in 29 and benign in 18 cases.
  • The algorithm for aneuploidy distinguished almost all tested malignant conditions from benign ones, also those with inconclusive cytology.
  • [MeSH-major] Breast Neoplasms / diagnosis. In Situ Hybridization, Fluorescence / methods. Lung Neoplasms / diagnosis. Mesothelioma / diagnosis. Pleural Neoplasms / diagnosis. Solitary Fibrous Tumor, Pleural / diagnosis
  • [MeSH-minor] Aneuploidy. Diagnosis, Differential. Female. Genes, p16. Humans. Pleural Effusion, Malignant / pathology. Reagent Kits, Diagnostic. Sequence Deletion / genetics

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 19523712.001).
  • [ISSN] 1872-8332
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Reagent Kits, Diagnostic
  •  go-up   go-down


45. Fu XY, Bin XN, Tan M: [Expressions of 8-OH-dG, k-ras, and p53 genes in pleural effusion cells and their clinical significances]. Ai Zheng; 2005 Mar;24(3):345-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • 8-hydoxy-2deoxy-guanosine (8-OH-dG), a biomarker of oxidative DNA damage, plays important roles in initiation, progression, and prognosis of lung cancer, and closely relates with mutations of k-ras and p53 genes in carcinogenesis of lung tissue.
  • This study was to detect protein expressions of 8-OH-dG, k-ras, and p53 genes in lung cancer tissues, and to analyze their values in distinguished diagnosis of lung cancer.
  • METHODS: Protein levels of 8-OH-dG, k-ras, and p53 in pleural effusion cells from 53 patients with lung cancer, and 53 patients with other benign lung diseases were detected by immunocytochemistry.
  • RESULTS: Positive rates of 8-OH-dG, k-ras, and p53 protein in cancer group were significantly higher than those in benign disease group [75.5% (40/53) vs. 15.1% (8/53), P < 0.01; 64.2% (34/53) vs. 3.8% (2/53), P < 0.01; and 69.8% (37/53) vs. 18.9% (10/53), P < 0.01; respectively].
  • CONCLUSIONS: Protein expressions of 8-OH-dG, k-ras, and p53 are up-regulated in pleural effusion cells of lung cancer, and have mutual relations.
  • They may be used as reference markers in diagnosing and screening for lung cancer.
  • [MeSH-major] Deoxyguanosine / analogs & derivatives. Lung Neoplasms / metabolism. Pleural Effusion, Malignant / metabolism. Tumor Suppressor Protein p53 / metabolism. ras Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Adenocarcinoma / metabolism. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Carcinoma, Small Cell / metabolism. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. Carcinoma, Squamous Cell / metabolism. Gene Expression Regulation, Neoplastic. Genes, p53. Genes, ras. Humans. Up-Regulation

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757539.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 88847-89-6 / 8-oxo-7-hydrodeoxyguanosine; EC 3.6.5.2 / ras Proteins; G9481N71RO / Deoxyguanosine
  •  go-up   go-down


46. Sun BL, Zhu L, Ding WF, Jing RR, Chu SP, Wang HM: [The diagnostic value of quantitative measurement of a proliferation-inducing ligand mRNA in sputum samples from lung cancer patients]. Zhonghua Jie He He Hu Xi Za Zhi; 2009 Mar;32(3):182-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The diagnostic value of quantitative measurement of a proliferation-inducing ligand mRNA in sputum samples from lung cancer patients].
  • OBJECTIVE: To establish a real-time fluorescence quantitative polymerase chain reaction (RFQ-PCR) method for quantifying a proliferation-inducing ligand (APRIL) mRNA in sputum samples from patients with non-small cell lung cancer (NSCLC), and to evaluate its role in the diagnosis of NSCLC.
  • METHODS: Seventy-one cases of NSCLC and 62 cases of benign pulmonary disease were enrolled in this study from August 2007 to May 2008 in Affiliated Hospital of Nantong University, Jiangsu.
  • The expression of APRIL mRNA in tumor sputum was higher than that in benign pulmonary disease and healthy volunteers (t = 10.50, 11.32, P < 0.01).
  • The positive rate for APRIL mRNA expression was 81.7% (58 of 71) in sputum samples of NSCLC, 3.2% (2/62) in benign pulmonary disease and 1.5% (1/65) in healthy volunteers when cut-off values for positivity were set at the x(-) +/- 2 s of mRNA expression in health volunteers.
  • The level of APRIL mRNA of NSCLC was not related to sex, age, smoking status, TNM stage and lymph node metastasis (P > 0.05, respectively), but was related to pathology subtype and the location of tumors (P < 0.05, respectively).
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / diagnosis. Lung Neoplasms / diagnosis. Polymerase Chain Reaction / methods. Sputum / chemistry
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Case-Control Studies. Female. Humans. Ligands. Male. Middle Aged. Neoplasm Staging. RNA, Messenger / analysis. Sensitivity and Specificity. Tumor Necrosis Factor Ligand Superfamily Member 13 / analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575936.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Ligands; 0 / RNA, Messenger; 0 / Tumor Necrosis Factor Ligand Superfamily Member 13
  •  go-up   go-down


47. Cerfolio RJ, Bryant AS: Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg; 2007 May;83(5):1826-9; discussion 1829-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer.
  • BACKGROUND: The maximum standardized uptake value (maxSUV) on F-18 fluorodeoxyglucose-positron emission tomography (FDG-PET) scan of mediastinal (N2) lymph nodes may predict pathology in patients with nonsmall-cell lung cancer.
  • Thus, we evaluated the ratio of the maxSUV of the lymph node to the primary tumor at different centers to determine whether it was a universal predictor of lymph node malignancy.
  • Patients with nonsmall-cell lung cancer, a dedicated FDG-PET with the maxSUV of the primary lung tumor and FDG-avid mediastinal (N2) nodes reported (before therapy), and who underwent lymph node removal were eligible.
  • The median ratio of the maxSUV of the lymph node to the maxSUV of the primary tumor of the pathologically proven malignant nodes was 0.58 (range, 0.32 to 1.61).
  • Benign nodes had a median ratio of 0.40 (range, 0.21 to 1.10, p = 0.02).
  • CONCLUSIONS: The ratio of the maxSUV of the mediastinal (N2) lymph node to the maxSUV of the primary tumor in patients with nonsmall-cell lung cancer predicts mediastinal nodal pathology across different PET centers.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacology. Lung Neoplasms / radionuclide imaging. Positron-Emission Tomography. Radiopharmaceuticals / pharmacology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymph Nodes / radionuclide imaging. Lymphatic Metastasis. Male. Mediastinum. Middle Aged. Neoplasm Staging. Predictive Value of Tests

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17462407.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


48. Joshi SC, Pant I, Khan FA, Shukla AN, Gokula K: Role of Integrated PET/CT Fusion in Lung Carcinoma. Int J Health Sci (Qassim); 2008 Jan;2(1):97-101
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Role of Integrated PET/CT Fusion in Lung Carcinoma.
  • Positron emission tomography has emerged as an important diagnostic tool in the management of lung cancers.
  • PET is sensitive in the detection of lung cancer, but FDG (2-deoxy-2-18fluro-D-glucose) is not tumor specific and may accumulate in a variety of non-malignant conditions occasionally giving false negative result.
  • The addition of CT to PET improves specificity foremost, but also sensitivity in tumor imaging.
  • PET/CT fusion images are useful in differentiating between malignant and benign disease, fibrosis and recurrence, staging and in changing patient management to a more appropriate therapy.
  • With analysis and discussion, it appears that PET/ CT fusion images have the potential to dramatically improve our ability to manage the patients with lung cancer and is contributing to our understanding of cancer cell biology and in the development of new therapies.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):551-60 [10837935.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):1075-84 [9508193.001]
  • [Cites] J Nucl Med. 2000 Aug;41(8):1369-79 [10945530.001]
  • [Cites] Ter Arkh. 2001;73(10):11-4 [11763507.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2002 Mar;29(3):346-50 [12002709.001]
  • [Cites] J Nucl Med. 2003 Feb;44(2):224-39 [12571214.001]
  • [Cites] J Nucl Med. 2003 Apr;44(4):540-8 [12679397.001]
  • [Cites] N Engl J Med. 2003 Jun 19;348(25):2500-7 [12815135.001]
  • [Cites] Radiology. 2003 Nov;229(2):526-33 [14512512.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):853-63 [14529793.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2004 Nov;31(11):1456-61 [15248033.001]
  • [Cites] J Nucl Med. 2004 Oct;45(10):1640-6 [15471827.001]
  • [Cites] AAPS J. 2006;8(3):E508-14 [17025269.001]
  • [Cites] J Nucl Med. 1996 Sep;37(9):1428-36 [8790186.001]
  • [Cites] Lung Cancer. 1998 Mar;19(3):167-77 [9631364.001]
  • [Cites] Radiology. 2002 Nov;225(2):575-81 [12409597.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2003 May;30(5):721-6 [12612809.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 May 1;59(1):78-86 [15093902.001]
  • [Cites] J Clin Oncol. 2004 Nov 1;22(21):4357-68 [15514377.001]
  • [Cites] Curr Med Chem. 2005;12(7):807-18 [15853713.001]
  • [Cites] J Appl Clin Med Phys. 2005 Fall;6(4):65-76 [16421501.001]
  • [Cites] J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50 [2013803.001]
  • [Cites] J Nucl Med. 1980 Jul;21(7):670-5 [7391842.001]
  • [Cites] Semin Nucl Med. 2000 Jul;30(3):150-85 [10928381.001]
  • (PMID = 21475478.001).
  • [ISSN] 1658-3639
  • [Journal-full-title] International journal of health sciences
  • [ISO-abbreviation] Int J Health Sci (Qassim)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC3068710
  • [Keywords] NOTNLM ; CAT scan (CT) / Lung carcinoma / Positron emission tomography (PET)
  •  go-up   go-down


49. Chen CH, Lai JM, Chou TY, Chen CY, Su LJ, Lee YC, Cheng TS, Hong YR, Chou CK, Whang-Peng J, Wu YC, Huang CY: VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway. PLoS One; 2009;4(4):e5052
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] VEGFA upregulates FLJ10540 and modulates migration and invasion of lung cancer via PI3K/AKT pathway.
  • BACKGROUND: Lung adenocarcinoma is the leading cause of cancer-related deaths among both men and women in the world.
  • Despite recent advances in diagnosis and treatment, the mortality rates with an overall 5-year survival of only 15%.
  • Although several well-known markers correlated with poor/metastasis prognosis in lung adenocarcinoma patients by immunohistochemistry was reported, the molecular mechanisms of lung adenocarcinoma development are still not clear.
  • To explore novel molecular markers and their signaling pathways will be crucial for aiding in treatment of lung adenocarcinoma patients.
  • METHODOLOGY/PRINCIPAL FINDINGS: To identify novel lung adenocarcinoma-associated /metastasis genes and to clarify the underlying molecular mechanisms of these targets in lung cancer progression, we created a bioinformatics scheme consisting of integrating three gene expression profile datasets, including pairwise lung adenocarcinoma, secondary metastatic tumors vs. benign tumors, and a series of invasive cell lines.
  • Among the novel targets identified, FLJ10540 was overexpressed in lung cancer tissues and is associated with cell migration and invasion.
  • Lung adenocarcinoma array profiles and tissue microarray IHC staining data showed that FLJ10540 and VEGF-A, as well as FLJ10540 and phospho-AKT exhibit positive correlations, respectively.
  • Stimulation of lung cancer cells with VEGF-A results in an increase in FLJ10540 protein expression and enhances complex formation with PI3K.
  • CONCLUSIONS/SIGNIFICANCE: This finding set the stage for further testing of FLJ10540 as a new therapeutic target for treating lung cancer and may contribute to the development of new therapeutic strategies that are able to block the PI3K/AKT pathway in lung cancer cells.
  • [MeSH-major] Adenocarcinoma / pathology. Cell Cycle Proteins / physiology. Lung Neoplasms / pathology. Neoplasm Invasiveness. Neoplasm Metastasis. Nuclear Proteins / physiology. Phosphatidylinositol 3-Kinases / metabolism. Proto-Oncogene Proteins c-akt / metabolism. Up-Regulation / physiology. Vascular Endothelial Growth Factor A / physiology
  • [MeSH-minor] Base Sequence. Cell Line, Tumor. Enzyme Activation. Gene Knockdown Techniques. Humans. Microscopy, Fluorescence. RNA, Messenger / genetics. RNA, Small Interfering. Reverse Transcriptase Polymerase Chain Reaction. Tissue Array Analysis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Cell. 2002 Apr;1(3):219-27 [12086857.001]
  • [Cites] Nature. 1999 Dec 2;402(6761):483-7 [10591207.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Pathol. 2003 Jul;200(3):336-47 [12845630.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):660-4 [12869408.001]
  • [Cites] Biochem Soc Trans. 2003 Dec;31(Pt 6):1171-7 [14641020.001]
  • [Cites] Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):294-300 [14656735.001]
  • [Cites] Mol Ther. 2004 Apr;9(4):510-8 [15093181.001]
  • [Cites] Nat Rev Cancer. 2004 Jun;4(6):423-36 [15170445.001]
  • [Cites] J Biol Chem. 2004 Jul 30;279(31):32592-602 [15145941.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):6865-71 [15501963.001]
  • [Cites] Apoptosis. 2004 Nov;9(6):667-76 [15505410.001]
  • [Cites] Cancer Metastasis Rev. 1996 Dec;15(4):507-25 [9034607.001]
  • [Cites] Int J Cancer. 1997 Feb 20;74(1):64-8 [9036871.001]
  • [Cites] Am J Respir Cell Mol Biol. 1997 Sep;17(3):353-60 [9308922.001]
  • [Cites] Br J Cancer. 1997;76(8):1041-5 [9376264.001]
  • [Cites] Cancer Res. 2001 Jan 15;61(2):589-93 [11212254.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):3986-97 [11358816.001]
  • [Cites] Cancer Res. 2001 Jul 1;61(13):5223-30 [11431363.001]
  • [Cites] Langenbecks Arch Surg. 2001 Jul;386(4):293-301 [11466572.001]
  • [Cites] FASEB J. 2001 Sep;15(11):1953-62 [11532975.001]
  • [Cites] J Natl Cancer Inst. 2001 Sep 19;93(18):1392-400 [11562390.001]
  • [Cites] Clin Cancer Res. 2001 Nov;7(11):3410-5 [11705856.001]
  • [Cites] Br J Cancer. 2002 Feb 12;86(4):558-63 [11870537.001]
  • [Cites] Science. 2002 May 31;296(5573):1655-7 [12040186.001]
  • [Cites] J Biol Chem. 1997 Dec 19;272(51):32521-7 [9405464.001]
  • [Cites] Clin Cancer Res. 1998 Jun;4(6):1483-7 [9626466.001]
  • [Cites] J Biol Chem. 1999 Apr 9;274(15):10002-7 [10187776.001]
  • [Cites] Am J Respir Crit Care Med. 1999 Oct;160(4):1269-73 [10508818.001]
  • [Cites] Lung. 2004;182(3):151-62 [15526754.001]
  • [Cites] Am J Respir Crit Care Med. 2004 Nov 15;170(10):1088-94 [15317667.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Dev Cell. 2005 Oct;9(4):477-88 [16198290.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Dec 16;338(2):830-8 [16256070.001]
  • [Cites] Oncogene. 2005 Nov 14;24(50):7443-54 [16288291.001]
  • [Cites] Mol Cell. 2005 Nov 23;20(4):539-50 [16307918.001]
  • [Cites] Cancer Res. 2006 Jan 1;66(1):46-51 [16397214.001]
  • [Cites] J Clin Oncol. 2006 Jan 10;24(2):306-14 [16330671.001]
  • [Cites] Oncogene. 2006 Jan 19;25(3):480-6 [16170351.001]
  • [Cites] Genomics. 2006 Feb;87(2):243-53 [16406728.001]
  • [Cites] Oncogene. 2006 Jan 26;25(4):609-21 [16158046.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]
  • [Cites] Cancer Lett. 2006 Apr 8;235(1):53-9 [15899546.001]
  • [Cites] Cell Cycle. 2006 Mar;5(6):603-5 [16582622.001]
  • [Cites] J Biol Chem. 2006 Aug 11;281(32):23285-95 [16787925.001]
  • [Cites] Mol Biol Cell. 2006 Sep;17(9):3881-96 [16790497.001]
  • [Cites] Curr Opin Investig Drugs. 2007 Feb;8(2):140-9 [17328230.001]
  • [Cites] J Biol Chem. 2007 Mar 16;282(11):7758-69 [17178724.001]
  • [Cites] Oncogene. 2007 Jun 21;26(29):4272-83 [17237822.001]
  • [Cites] Crit Rev Oncol Hematol. 2007 Aug;63(2):172-82 [17540577.001]
  • [Cites] CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96 [18287387.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Behav Brain Res. 2002 Nov 15;136(2):489-501 [12429412.001]
  • (PMID = 19337377.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Cep55 protein, human; 0 / Nuclear Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0 / Vascular Endothelial Growth Factor A; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  • [Other-IDs] NLM/ PMC2659802
  •  go-up   go-down


50. Nadelman CM, Leslie KO, Fishbein MC: "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases. Arch Pathol Lab Med; 2006 Sep;130(9):1349-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] "Benign," metastasizing adenomyoepithelioma of the breast: a report of 2 cases.
  • Adenomyoepitheliomas of the breast are rare tumors composed of a proliferation of 2 cell populations.
  • For the most part, they are considered to be benign, but they locally recur.
  • Those neoplasms that metastasize are deemed to have come from a histologically malignant primary tumor.
  • Herein, we describe 2 cases of metastases of histologically "benign" adenomyoepitheliomas of the breast to the lung.
  • Establishing the diagnosis, determining optimal therapy, and predicting outcome are problematic because of the rarity of this entity.
  • [MeSH-minor] Aged. Female. Humans. Lung Neoplasms / radiography. Middle Aged. Neoplasm Metastasis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16948523.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


51. Shimizu K, Okita R, Hamai Y: [Intrabronchial leiomyoma treated with endoscopic resection; report of a case]. Kyobu Geka; 2008 Feb;61(2):168-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A serial chest computed tomography (CT) showed ground-glass attenuation, which measured 2 cm on S1+2 of the left lung.
  • When bronchofiberscopy was performed to make a diagnosis, a tumor with a smooth surface was revealed which obstructed the right middle bronchus.
  • At first, a wide wedge resection of left lung tumor was performed.
  • Secondly, a bronchus tumor was successively removed using a high frequency snare and a laser by a bronchofiberscopy.
  • Leiomyoma of the bronchus is rare benign tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18268959.001).
  • [ISSN] 0021-5252
  • [Journal-full-title] Kyobu geka. The Japanese journal of thoracic surgery
  • [ISO-abbreviation] Kyobu Geka
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


52. Bernabé DG, Veronese LA, Miyahara GI, Conrado-Neto S, Biasoli ER: Gingival metastasis from salivary duct carcinoma of the parotid gland. J Periodontol; 2008 Apr;79(4):748-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The intraoral examination revealed a reddish, superficially ulcerated nodular lesion ( approximately 2 cm in diameter) on the right mandibular buccal attached gingiva, and the clinical aspect was that of a benign reactive lesion.
  • RESULTS: The analysis of the histopathologic sections of the gingival lesion revealed histomorphologic characteristics very similar to those of the primary parotid gland tumor.
  • The definitive diagnosis was gingival metastasis from a salivary duct carcinoma of the parotid gland.
  • The patient died of complications of a pulmonary metastasis 1 month after the diagnosis of the oral metastatic lesion.
  • An accurate and timely diagnosis is crucial to establish proper and immediate treatment of the metastatic tumor and possibly identify an occult primary malignant neoplasia.
  • [MeSH-minor] Aged. Fatal Outcome. Humans. Lung Neoplasms / secondary. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18380570.001).
  • [ISSN] 0022-3492
  • [Journal-full-title] Journal of periodontology
  • [ISO-abbreviation] J. Periodontol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


53. Fulkerson DH, Horner TG, Hattab EM: Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature. Clin Neurol Neurosurg; 2008 Apr;110(4):416-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histologically benign intraventricular meningioma with concurrent pulmonary metastasis: case report and review of the literature.
  • Metastasis from a histologically "benign" meningioma is a rare, but well-documented event.
  • The tumors in these reports had a frankly malignant histology or were associated with surgical manipulation and recurrence of the primary lesion.
  • In this report, the authors present a rare case of the concurrent presentation of a histologically benign intraventricular meningioma and a solitary lung lesion which proved to be metastatic meningioma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / pathology. Lung Neoplasms / secondary. Magnetic Resonance Imaging. Meningeal Neoplasms / pathology. Meningioma / secondary. Tomography, X-Ray Computed
  • [MeSH-minor] Biomarkers, Tumor / analysis. Biopsy, Needle. Humans. Ki-67 Antigen / analysis. Lung / pathology. Male. Middle Aged. Mitotic Index. Mucin-1 / analysis. Receptors, Progesterone / analysis


54. Hanley KZ, Facik MS, Bourne PA, Yang Q, Spaulding BO, Bonfiglio TA, Xu H: Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions. Cancer; 2008 Feb 25;114(1):49-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
  • Using a mouse monoclonal antibody (L523S) against KOC, KOC expression was investigated in malignant tumors and reactive mesothelial cells in serous effusions.
  • METHODS: Seventy-six cases with paraffin-embedded pleural, pericardial, and peritoneal serous effusion cell blocks including 60 malignant serous effusions (11 malignant pleural mesotheliomas and 49 metastatic carcinomas) and benign pleural effusions (14 cases with reactive mesothelial cells and 2 cases with atypical cells with uncertain significance) were selected for immunohistochemical analysis with L523S, calretinin, and CK5/6.
  • Interestingly, 3 of 16 cases exhibited various degrees of positivity for KOC, 2 of which were diagnosed as lung adenocarcinoma with a recurrence after tumor resection and 1 as malignant pleural mesothelioma.
  • [MeSH-major] Biomarkers, Tumor / analysis. Mesothelioma / diagnosis. Neoplasm Proteins / analysis. Pleural Effusion / diagnosis. Pleural Effusion, Malignant / diagnosis. RNA-Binding Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Ascitic Fluid / chemistry. Calbindin 2. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis. Pericardial Effusion / chemistry. S100 Calcium Binding Protein G / analysis

  • MedlinePlus Health Information. consumer health - Mesothelioma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society
  • (PMID = 18098206.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calb2 protein, mouse; 0 / Calbindin 2; 0 / IMP3 protein, human; 0 / Neoplasm Proteins; 0 / RNA-Binding Proteins; 0 / S100 Calcium Binding Protein G
  •  go-up   go-down


55. Schmidt B, Weickmann S, Witt C, Fleischhacker M: Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease. Ann N Y Acad Sci; 2008 Aug;1137:207-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Integrity of cell-free plasma DNA in patients with lung cancer and nonmalignant lung disease.
  • We isolated cell-free DNA from plasma, serum, and bronchial lavage supernatants from 33 lung cancer patients and 27 patients with a benign lung disease.
  • Our results led us to conclude that this method is not useful in a diagnostic setting and is not able to differentiate between lung cancer patients and patients with a benign lung disease.
  • [MeSH-major] Biomarkers, Tumor. DNA / blood. DNA, Neoplasm / blood. Lung Diseases. Lung Neoplasms
  • [MeSH-minor] Aged. Aged, 80 and over. Bronchoalveolar Lavage Fluid / chemistry. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Diseases.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837948.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 9007-49-2 / DNA
  •  go-up   go-down


56. Schmidt B, Engel E, Carstensen T, Weickmann S, John M, Witt C, Fleischhacker M: Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection? Lung Cancer; 2005 Apr;48(1):145-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Quantification of free RNA in serum and bronchial lavage: a new diagnostic tool in lung cancer detection?
  • In cancer patients levels of free DNA seem to be higher than in non-tumor controls and the detectable nucleic acids are partly of tumor origin.
  • We asked whether free RNA can be detected as well in cell-free bronchial lavage fluid (BLF) supernatant, and whether quantification of free RNA allows to discriminate between tumor and non-tumor patients.
  • 73 patients with lung cancer (NSCLC n=62, SCLC n=11) and 56 patients with non-malignant lung diseases were included.
  • RNA concentration in the BLF from tumor patients was higher than in patients with a benign lung disease (p=0.009).
  • In conclusion, quantification of intact RNA isolated from BLF supernatant and from serum might become a valuable tool for differentiation between tumor and non-tumor patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / diagnosis. Carcinoma, Non-Small-Cell Lung / genetics. Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / genetics. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics. RNA / blood
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Bronchoalveolar Lavage Fluid / chemistry. DNA, Neoplasm. Female. Humans. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15777983.001).
  • [ISSN] 0169-5002
  • [Journal-full-title] Lung cancer (Amsterdam, Netherlands)
  • [ISO-abbreviation] Lung Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm; 63231-63-0 / RNA
  •  go-up   go-down


57. Gesierich W, Diwersy C, Leinsinger G, Massmann J, Präuer H, Höfler H, Fend F, Emslander HP: [Papillary adenoma of type-II pneumocytes as a rare differential diagnosis of a solitary pulmonary nodule]. Pneumologie; 2007 Nov;61(11):697-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Papillary adenoma of type-II pneumocytes as a rare differential diagnosis of a solitary pulmonary nodule].
  • [Transliterated title] Papilläres Adenom der Typ-II-Pneumozyten als seltene Differenzialdiagnose eines pulmonalen Rundherdes.
  • Following the coincidental radiologic finding of a solitary pulmonary nodule, the diagnosis could be established in a bronchoscopically obtained endobronchial biopsy.
  • Papillary adenoma of type-II pneumocytes is a rare tumor, whose origin is suspected in progenitor cells of the bronchioloalveolar epithelium with the potential to differentiate towards type-II pneumocytes and clara cells.
  • The tumor is regarded as benign, however, a malignant potential is not excluded by some authors.
  • [MeSH-major] Adenoma / diagnosis. Lung / pathology. Lung Neoplasms / diagnosis. Solitary Pulmonary Nodule / etiology
  • [MeSH-minor] Aged. Biopsy. Bronchoscopy. Diagnosis, Differential. Humans. Incidental Findings. Male. Pneumonectomy. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17886196.001).
  • [ISSN] 1438-8790
  • [Journal-full-title] Pneumologie (Stuttgart, Germany)
  • [ISO-abbreviation] Pneumologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


58. Liu T, Wang X, Zhu C, Li Y, Sun C, Wang A: [Expression of KAI1 protein in tissue microarray and its biological significances in patients with lung cancer]. Zhongguo Fei Ai Za Zhi; 2005 Apr 20;8(2):116-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of KAI1 protein in tissue microarray and its biological significances in patients with lung cancer].
  • BACKGROUND: KAI1 is a new identified metastasis-suppressor gene whose expression in many types of tumors has been reported.
  • The aim of study is to investigate the role of KAI1 protein in development of lung cancer and its values in predicting the prognosis of lung cancer.
  • METHODS: The expressions of KAI1 protein were detected in benign pulmonary disease tissue, precancerous disease tissue, lung cancer tissue and metastatic lung cancer tissue in local lymph node using tissue microarray and immunohistochemical method.
  • The relationship between expression of KAI1 protein and clinicopathological parameters of patients with lung cancer was analyzed by Chi-Square test and Fisher exact test.
  • RESULTS: The positive rate of KAI1 expression was 100.0% in 10 cases of benign pulmonary diseases, 66.7% in 12 cases of precancerous diseases, 24.7% in 89 cases of primary lung cancer and 0 in metastatic lung cancer tissue in local lymph node respectively.
  • The KAI1 protein expression in primary lung cancer tissues had no remarkable relationship with age and gender of the patients and the location of cancer, but had significant relationship with the histological type and differentiated degree of tumor, P-TNM stages and lymph node metastatic status.
  • CONCLUSIONS: The abnormal expression of KAI1 protein may participate in malignant progression of lung cancer.
  • Its downregulation may promote the invasion and metastasis of tumor cell.
  • Detection of the expression of KAI1 protein may be helpful to predict the prognosis of lung cancer.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21189178.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


59. Gu W, Sun LH, Fang SR, Ma JY, Zhang AP, Chen L: [Clinical analysis of the rare causes of hemoptysis: a report of 4 cases]. Zhonghua Jie He He Hu Xi Za Zhi; 2007 May;30(5):343-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To improve the diagnosis of hemoptysis caused by rare lung diseases.
  • For PH, a benign tumor, the diagnosis was based on the history and radiography examination, and operation was the choice for therapy.
  • The diagnosis of PPH was firstly evaluated by chest film and echocardiogram, and the final diagnosis relied on right cardiac catheter examination.
  • The correct diagnosis and therapy rely on comprehensive thinking, careful history collection and reasonable examinations.

  • MedlinePlus Health Information. consumer health - Pulmonary Hypertension.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17651639.001).
  • [ISSN] 1001-0939
  • [Journal-full-title] Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
  • [ISO-abbreviation] Zhonghua Jie He He Hu Xi Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


60. Jungraithmayr W, Hasse J, Olschewski M, Stoelben E: [Completion pneumonectomy. Indications and results]. Chirurg; 2005 Feb;76(2):157-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The results of the following CPs (N=86) were investigated: progressive or recurrent benign disease (N=6, group I), recurrence of a malignant tumor (N=41, group II), and complication after lung resection (N=39, group III).
  • Five-year survival was 26% in the group of patients with malignant disease and 32% in those with complications after lung resection.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / surgery. Empyema / surgery. Lung Neoplasms / surgery. Neoplasms, Second Primary / surgery. Pneumonectomy. Tuberculosis, Pulmonary / surgery
  • [MeSH-minor] Adult. Aged. Emergencies. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Postoperative Complications. Prognosis. Reoperation. Risk Factors. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Thorac Cardiovasc Surg. 1995 Oct;110(4 Pt 1):1125-9 [7475141.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Jun;121(6):1076-82 [11385374.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Nov;12(5):694-7 [9458137.001]
  • [Cites] Ann Thorac Surg. 1988 Aug;46(2):141-6 [3401074.001]
  • [Cites] Ann Thorac Surg. 1992 Jun;53(6):1042-5 [1596126.001]
  • [Cites] J Thorac Cardiovasc Surg. 2001 Mar;121(3):484-90 [11241083.001]
  • [Cites] Thorac Cardiovasc Surg. 1995 Feb;43(1):52-6 [7540330.001]
  • [Cites] Eur J Cardiothorac Surg. 1996;10(4):238-41 [8740058.001]
  • [Cites] Ann Thorac Surg. 2002 Sep;74(3):876-83; discussion 883-4 [12238854.001]
  • [Cites] Ann Thorac Surg. 1995 Jan;59(1):196-200 [7818323.001]
  • [Cites] Chest. 1998 Oct;114(4):1158-84 [9792592.001]
  • [Cites] J Thorac Cardiovasc Surg. 1993 May;105(5):918-24 [8487570.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Jun;117(6):1095-101 [10343257.001]
  • [Cites] J Thorac Cardiovasc Surg. 1983 Nov;86(5):654-8 [6632940.001]
  • [Cites] Ann Thorac Surg. 2001 Jul;72(1):243-7; discussion 248 [11465187.001]
  • [Cites] Ann Thorac Surg. 1989 Jul;48(1):33-7 [2764597.001]
  • (PMID = 15258743.001).
  • [ISSN] 0009-4722
  • [Journal-full-title] Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen
  • [ISO-abbreviation] Chirurg
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


61. Park JY, Park KH, Bang S, Kim MH, Lee JE, Gang J, Koh SS, Song SY: CXCL5 overexpression is associated with late stage gastric cancer. J Cancer Res Clin Oncol; 2007 Nov;133(11):835-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Chemokines play multiple roles in the development and progression of many different tumors.
  • The intensity of immunostaining in tumor tissue was considered strong when tumor tissue staining was more intense than in normal tissue; the intensity was null when staining was weaker in the tumor than in normal tissue; and the intensity was weak when staining was similar in both tissues.
  • Serum CXCL5 levels and microvascular density in tumor tissue were measured by ELISA and monoclonal antibody to Factor VIII.
  • RESULTS: Strong CXCL5 expression correlated with tumor stage.
  • Serum CXCL5 levels in late stage (IIIB, IV) gastric cancer patients were higher than in patients with benign conditions.
  • Microvascular density was higher in tumors with strong CXCL5 expression, but the correlation with CXCL5 was not linear.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Chemokine CXCL5 / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Carcinoma, Signet Ring Cell / metabolism. Carcinoma, Signet Ring Cell / pathology. Female. Gastrectomy. Gastric Mucosa / metabolism. Gastric Mucosa / pathology. Gene Expression Regulation, Neoplastic. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2001 Jun;280(6):L1094-103 [11350788.001]
  • [Cites] Am J Surg. 1983 Feb;145(2):226-33 [6824136.001]
  • [Cites] J Biol Chem. 2004 Jan 30;279(5):3188-96 [14625285.001]
  • [Cites] J Biol Chem. 2003 Feb 14;278(7):4675-86 [12468547.001]
  • [Cites] Ann Surg. 1993 Nov;218(5):583-92 [8239772.001]
  • [Cites] J Clin Oncol. 2003 Oct 1;21(19):3647-50 [14512396.001]
  • [Cites] Am J Respir Crit Care Med. 2003 Oct 15;168(8):968-75 [12857718.001]
  • [Cites] J Biol Chem. 2001 Mar 30;276(13):9945-54 [11136732.001]
  • [Cites] Semin Cancer Biol. 2002 Apr;12(2):89-96 [12027580.001]
  • [Cites] J Biol Chem. 2000 Mar 10;275(10):6868-75 [10702246.001]
  • [Cites] J Clin Invest. 1995 Jan;95(1):134-41 [7814607.001]
  • [Cites] Cancer. 2000 Feb 15;88(4):921-32 [10679663.001]
  • [Cites] Blood. 2001 Jan 15;97(2):339-45 [11154206.001]
  • [Cites] Biochemistry. 2002 Jun 4;41(22):7100-7 [12033944.001]
  • [Cites] Dig Surg. 1998;15(4):317-22 [9845606.001]
  • [Cites] Clin Cancer Res. 2004 Aug 1;10(15):4895-900 [15297389.001]
  • [Cites] J Gastroenterol Hepatol. 2004 Sep;19(9):982-7 [15304113.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):853-60 [12576459.001]
  • [Cites] J Clin Invest. 1996 Jun 15;97(12):2792-802 [8675690.001]
  • [Cites] J Clin Pathol. 1998 Oct;51(10):765-70 [10023340.001]
  • [Cites] World J Surg. 2002 Mar;26(3):323-9 [11865369.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Mod Pathol. 2002 Aug;15(8):831-7 [12181268.001]
  • [Cites] Cancer Res. 2006 Apr 15;66(8):4279-84 [16618752.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Proc Natl Acad Sci U S A. 1989 Aug;86(15):5859-63 [2762301.001]
  • [Cites] J Gastroenterol Hepatol. 1998 May;13(5):516-20 [9641651.001]
  • [Cites] J Clin Invest. 1998 Aug 1;102(3):465-72 [9691082.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] J Interferon Cytokine Res. 2002 Oct;22(10):1067-8 [12433287.001]
  • [Cites] J Cell Sci. 2001 Aug;114(Pt 15):2713-22 [11683406.001]
  • [Cites] Hepatology. 1998 Feb;27(2):507-12 [9462650.001]
  • [Cites] Clin Cancer Res. 2004 Apr 1;10(7):2393-400 [15073116.001]
  • [Cites] World J Surg. 1984 Jun;8(3):308-14 [6464487.001]
  • [Cites] J Exp Med. 1991 Dec 1;174(6):1355-62 [1744577.001]
  • [Cites] Immunity. 2000 Feb;12(2):121-7 [10714678.001]
  • (PMID = 17479287.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CXCL5 protein, human; 0 / Chemokine CXCL5
  •  go-up   go-down


62. Parfitt JR, Bella AJ, Izawa JI, Wehrli BM: Malignant neoplasm of perivascular epithelioid cells of the liver. Arch Pathol Lab Med; 2006 Aug;130(8):1219-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant neoplasm of perivascular epithelioid cells of the liver.
  • Although this group includes entities with distinct clinical features, such as angiomyolipoma, clear cell sugar tumor of the lung, and lymphangioleiomyomatosis, similar tumors have been documented in an increasing diversity of locations.
  • The term PEComa is now generally used in reference to these lesions that are not angiomyolipomas, clear cell sugar tumors, or lymphangioleiomyomatoses.
  • While most reported PEComas have behaved in a benign fashion, malignant PEComas have occasionally been documented.
  • We present a case of hepatic PEComa with benign histologic features, which nonetheless presented with metastases to multiple sites nearly 9 years later.

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16879028.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


63. Qian W, Zhukov T, Song D, Tockman MS: Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer. Anal Quant Cytol Histol; 2007 Apr;29(2):103-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Computerized analysis of cellular features and biomarkers for cytologic diagnosis of early lung cancer.
  • OBJECTIVE: To present a set of novel computerized analysis algorithms to construct a computer-aided cytologic diagnosis (CACD) system to differentiate lung cancer biomarkers and identify cancer cells in the tissue-based specimen images.
  • STUDY DESIGN: Molecular methods, including application of cancer-specific markers, may prove to be complementary to cytology diagnosis, especially when they are combined with CACD system for biomarker assessment.
  • We trained a novel CACD system to recognize expression of the cancer biomarkers histone H2AX in lung cancer cells and then tested the accuracy of this system to distinguish resected lung cancer from preneoplastic and normal tissues.
  • CONCLUSION: The presented algorithms and CACD system for cellular feature enhancement, segmentation and classification are very important in distinguishing benign and malignant lesions.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17484274.001).
  • [ISSN] 0884-6812
  • [Journal-full-title] Analytical and quantitative cytology and histology
  • [ISO-abbreviation] Anal. Quant. Cytol. Histol.
  • [Language] ENG
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


64. Chae EJ, Song JW, Krauss B, Song KS, Lee CW, Lee HJ, Seo JB: Dual-energy computed tomography characterization of solitary pulmonary nodules. J Thorac Imaging; 2010 Nov;25(4):301-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In particular, the degree of enhancement of an SPN after iodine injection has been shown to be helpful in distinguishing malignant from benign nodules.
  • This technique may have applications in contrast-enhanced dynamic CT and perfusion CT for the differentiation between benign and malignant lesions and the assessment of tumor angiogenesis.
  • In addition, we briefly review the physical principles of dual-energy CT and discuss potential future applications in patients with lung nodules.

  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21042068.001).
  • [ISSN] 1536-0237
  • [Journal-full-title] Journal of thoracic imaging
  • [ISO-abbreviation] J Thorac Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


65. Zheng JP, Shao GL, Chen YT, Fan SF, Yang JM: [Feasibility study on CT guided percutaneous incisional needle biopsy for deep pelvic masses by different puncture approaches]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):786-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Sixty-four malignant lesions were confirmed by pathology, including 30 adenocarcinomas, 19 squamous cell carcinomas, 5 unclassified malignant tumors, 3 small cell carcinomas, 2 malignant giant cell tumors of bone, 2 hepatocellular carcinomas and 3 false negative lesions which were confirmed at the second PINBs as malignant tumors, respectively.
  • Benign neoplasms were confirmed in 8 cases, including fibrosis tissue in 6 lesions, bone tuberculosis in 1 and ovarian cyst in 1.
  • No hematoma, nerve damage, infection, and tumor transplantation in pelvic cavity developed after the PINB procedure.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Colorectal Neoplasms / radiography. Diagnosis, Computer-Assisted / methods. Feasibility Studies. Female. Fibrosis / pathology. Fibrosis / radiography. Follow-Up Studies. Humans. Lung Neoplasms / pathology. Lung Neoplasms / radiography. Male. Middle Aged. Tomography, X-Ray Computed. Uterine Neoplasms / pathology. Uterine Neoplasms / radiography

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021836.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


66. Kruscić D, Peco-Antić A, Spasojević-Dimitrijeva B, Stanić M, Milosevski-Lomić G, Kostić M, Ivanovski P, Boricić I: Pulmonary inflammatory myofibroblastic tumor associated with nephrotic syndrome. Pediatr Nephrol; 2007 Oct;22(10):1785-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary inflammatory myofibroblastic tumor associated with nephrotic syndrome.
  • Inflammatory myofibroblastic tumor (IMT) of the lung is a benign, non-metastasizing tumor with the possibility of local infiltration, recurrence or persistent local growth.
  • This kind of tumor arises due to an unregulated growth of inflammatory cells.
  • Therefore, we present the case of a 14-year-old girl with lung IMT associated with secondary nephrotic syndrome (NS), which was cured after tumor removal.
  • [MeSH-major] Fibrosarcoma / complications. Lung Neoplasms / complications. Nephrotic Syndrome / complications


67. Kuruvilla S, Saldanha R, Joseph LD: Recurrent respiratory papillomatosis complicated by aspergillosis: a case report with review of literature. J Postgrad Med; 2008 Jan-Mar;54(1):32-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary extension of recurrent invasive papillomatosis often poses a diagnostic challenge to the examining bronchoscopist, pathologist, radiologist and surgeon, in distinguishing it as a benign lesion that is confined to the mucosa and extending along the branches of the tracheobronchial tree from true invasion of a malignant tumor.
  • [MeSH-major] Aspergillosis / virology. Lung Diseases, Fungal / virology. Lung Neoplasms / secondary. Papilloma / radiography
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Humans. Itraconazole / administration & dosage. Itraconazole / therapeutic use. Male. Recurrence. Tomography, X-Ray Computed. Treatment Outcome


68. Andino L, Cagle PT, Murer B, Lu L, Popper HH, Galateau-Salle F, Sienko AE, Barrios R, Zander DS: Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression. Arch Pathol Lab Med; 2006 Oct;130(10):1503-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pleuropulmonary desmoid tumors: immunohistochemical comparison with solitary fibrous tumors and assessment of beta-catenin and cyclin D1 expression.
  • CONTEXT: Desmoid tumors arising in the lung and pleura are extremely rare and can resemble other, more common neoplasms native to these sites.
  • Alterations of the adenomatous polyposis coli/beta-catenin pathway have been detected in sporadic desmoid tumors and have been associated with nuclear accumulation of beta-catenin and overexpression of cyclin D1.
  • OBJECTIVE: To analyze the expression of beta-catenin and cyclin D1 in desmoid tumors and solitary fibrous tumors (SFTs), and to compare the utilities of these substances for distinguishing between these entities with those of other, more commonly used stains.
  • DESIGN: Formalin-fixed, paraffin-embedded sections of 4 desmoid tumors (1 pulmonary, 1 pleural, 2 pleural/chest wall), and 5 benign and 6 malignant SFTs of the pleura were immunostained for beta-catenin, cyclin D1, ALK1, CD34, vimentin, desmin, smooth muscle actin, muscle-specific actin, S100, and pancytokeratin.
  • Staining intensity and the percentage of stained tumor cells were assessed semiquantitatively.
  • RESULTS: Diffuse moderate or strong nuclear staining for beta-catenin was found in all desmoid tumors, 4 of 5 benign SFTs, and 2 of 6 malignant SFTs.
  • All cases except 1 benign SFT showed concurrent cytoplasmic staining.
  • The best distinction between desmoid tumors and SFTs was provided by CD34 (desmoid tumors, 0/4; SFTs, 8/11) and smooth muscle actin (desmoid tumors, 4/4; SFTs, 0/11).
  • CONCLUSIONS: Our findings suggest that alterations in the adenomatous polyposis coli/beta-catenin pathway and cyclin D1 dysregulation may contribute to the pathogenesis of pleuropulmonary desmoid tumors and SFTs.
  • CD34 and smooth muscle actin stains are particularly useful for differentiating between pleuropulmonary desmoid tumors and SFTs.
  • [MeSH-major] Cyclin D1 / metabolism. Leiomyoma / metabolism. Lung Neoplasms / metabolism. Pleural Neoplasms / metabolism. beta Catenin / metabolism
  • [MeSH-minor] Actins / metabolism. Adult. Aged. Antigens, CD34 / metabolism. Cell Nucleus / metabolism. Child, Preschool. Cytoplasm / metabolism. Diagnosis, Differential. Female. Fibromatosis, Aggressive. Humans. Immunohistochemistry. Male. Middle Aged. Muscle, Smooth / metabolism. Staining and Labeling

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17090192.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antigens, CD34; 0 / beta Catenin; 136601-57-5 / Cyclin D1
  •  go-up   go-down


69. Yang YJ, Cheng DY, Fang X, Li XX: [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer]. Sichuan Da Xue Xue Bao Yi Xue Ban; 2007 Mar;38(2):312-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The clinical diagnosis value of fibro-optic bronchoscope examination combined with tumor marker determination to lung cancer].
  • OBJECTIVE: To investigate the diagnosis value of fibro-optic-bronchoscope combined with tumor maker determination to lung cancer.
  • METHODS: By fibro-optic bronchoscope (FB) and electrochemiluminescence (ECL) examinations, 98 cases with lung cancer and 88 cases with benign lung disease were studied for calculating the detectable sensitivity and specificity to lung cancer, then further for evaluating the clinical value of FB examination combined with detection of tumor marker in serum/pleural fluid of patients with lung cancer.
  • Results In patients with lung cancer, the serum levels of CEA, CA125 and CYFRA21-1 were (46.34 +/- 18.28) ng/mL, (83.34 +/- 33.26) U/mL and (25.67 +/- 10.32) ng/mL respectively, which were higher than those in patients with benign lung diseases.
  • The serum levels of above three tumor markers in patients with lung cancer all were significantly higher than those in patients with benign lung diseases (P < 0.05).
  • In the 36 specimens of pleural fluid, three tumor markers were higher than those in the corresponding serum samples.
  • The detectable sensitivity of each tumor marker in pleural fluid was higher than that in serum.
  • The sensitivity, specificity and overall accuracy of CEA in lung cancer were 37.5%, 87.5% and 63.6% respectively, of CA125 were 67.7%, 40.9% and 54.9%; of CYFRA21-1 were 56.3%, 81.8% and 68.5%; of FB were 60.4%, 100.0% and 79.4% respectively.
  • The sensitivity, specificity or overall accuracy of fibro-optic bronchoscope combined with tumor marker (TM) examination to diagnosis of lung cancer was 90.6%, 92.0% or 91.3% respectively.
  • CONCLUSION: The FB examination is valuable in diagnosing lung cancer, and by combined with TM determination, can further improve the accuracy to diagnosis of lung cancer.
  • [MeSH-major] Biomarkers, Tumor / blood. Bronchoscopy / methods. Lung Neoplasms / blood. Lung Neoplasms / diagnosis. Optical Fibers

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17441358.001).
  • [ISSN] 1672-173X
  • [Journal-full-title] Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
  • [ISO-abbreviation] Sichuan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


70. Ngaage DL, Mullany CJ, Daly RC, Dearani JA, Edwards WD, Tazelaar HD, McGregor CG, Orszulak TA, Puga FJ, Schaff HV, Sundt TM 3rd, Zehr KJ: Surgical treatment of cardiac papillary fibroelastoma: a single center experience with eighty-eight patients. Ann Thorac Surg; 2005 Nov;80(5):1712-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Cardiac papillary fibroelastoma is a rare benign tumor that can cause thromboembolism.
  • METHODS: A retrospective review of all patients treated surgically for this tumor from 1985 to 2002.
  • Surgical mortality occurred in 1 patient (2.1%) in group 1 who had concomitant lung resection for bronchiolitis obliterans.
  • There was no tumor recurrence, and no tumor-related late morbidity or mortality at a mean follow-up of 3 years.

  • MedlinePlus Health Information. consumer health - Heart Valve Diseases.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Thorac Surg. 2006 Jul;82(1):381 [16798262.001]
  • (PMID = 16242444.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


71. Hu R, Li H: Giant cystic hemolymphangioma of the postmediastinum. Thorac Cancer; 2010 Nov;1(4):175-177
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) of the chest revealed a mediastinal tumor identified a giant non-invasive monomorphic cystic mass, in contact with the tracheal wall, arcus aortae and subclavian artery.
  • Partial excision of the mass was achieved through left thorascopic exploration, Frozen section margin examination suggests hemolymphangioma, which is a benign tumor.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © Tianjin Lung Cancer Institute and Blackwell Publishing Asia Pty. Ltd.
  • (PMID = 27755814.001).
  • [ISSN] 1759-7714
  • [Journal-full-title] Thoracic cancer
  • [ISO-abbreviation] Thorac Cancer
  • [Language] eng
  • [Publication-type] Case Reports
  • [Publication-country] Singapore
  • [Keywords] NOTNLM ; Hemolymphangioma / mediastinum / treatment
  •  go-up   go-down


72. Thompson CC, Ashcroft FJ, Patel S, Saraga G, Vimalachandran D, Prime W, Campbell F, Dodson A, Jenkins RE, Lemoine NR, Crnogorac-Jurcevic T, Yin HL, Costello E: Pancreatic cancer cells overexpress gelsolin family-capping proteins, which contribute to their cell motility. Gut; 2007 Jan;56(1):95-106
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunohistochemical analysis of benign (n = 44 patients) and malignant (n = 69) pancreatic ductal cells showed significantly higher CapG staining intensity in nuclear (p<0.001) and cytoplasmic (p<0.001) compartments of malignant cells.
  • Similarly, gelsolin immunostaining of benign (n = 24 patients) and malignant (n = 68 patients) pancreatic ductal cells showed higher expression in both compartments (both p<0.001).
  • High nuclear CapG was associated with increased tumour size (p = 0.001).
  • [MeSH-major] Cell Movement / physiology. Gelsolin / analysis. Microfilament Proteins / analysis. Neoplasm Proteins / analysis. Nuclear Proteins / analysis. Pancreatic Neoplasms / chemistry
  • [MeSH-minor] Adenocarcinoma / chemistry. Adenocarcinoma / genetics. Adenocarcinoma / pathology. Cell Line, Tumor. Cell Nucleus / metabolism. Cytoplasm / metabolism. Female. Humans. Isomerism. Kaplan-Meier Estimate. Male. Middle Aged. Pancreas / metabolism. Pancreas / pathology. Pancreatic Ducts / metabolism. Pancreatic Ducts / pathology. RNA Interference / physiology. RNA, Neoplasm / metabolism. Up-Regulation

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] EMBO J. 2002 Dec 16;21(24):6781-90 [12485999.001]
  • [Cites] Cancer. 2002 Sep 15;95(6):1247-57 [12216092.001]
  • [Cites] Nat Rev Cancer. 2003 May;3(5):362-74 [12724734.001]
  • [Cites] J Biol Chem. 2003 May 16;278(20):17945-52 [12637565.001]
  • [Cites] J Biol Chem. 2003 Aug 1;278(31):29136-44 [12754261.001]
  • [Cites] Infect Immun. 2003 Nov;71(11):6582-90 [14573680.001]
  • [Cites] Proteomics. 2003 Oct;3(10):1988-2001 [14625861.001]
  • [Cites] Mol Cancer. 2003 Jan 22;2:14 [12605717.001]
  • [Cites] Lung Cancer. 2004 Oct;46(1):29-42 [15364130.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5283-92 [15454578.001]
  • [Cites] Nature. 1979 Oct 18;281(5732):583-6 [492320.001]
  • [Cites] Science. 1990 Dec 7;250(4986):1413-5 [2255912.001]
  • [Cites] Science. 1991 Mar 8;251(4998):1233-6 [1848726.001]
  • [Cites] J Biol Chem. 1993 Feb 25;268(6):4106-12 [8382692.001]
  • [Cites] Cell Motil Cytoskeleton. 1993;26(3):227-38 [8293478.001]
  • [Cites] J Cell Biol. 1995 Apr;129(1):147-56 [7698981.001]
  • [Cites] Cancer Res. 1995 Aug 1;55(15):3228-32 [7614452.001]
  • [Cites] J Cell Biol. 1997 Sep 22;138(6):1279-87 [9298983.001]
  • [Cites] Cancer Res. 1998 Jan 15;58(2):322-7 [9443412.001]
  • [Cites] Biochim Biophys Acta. 1998 Dec 10;1448(2):290-7 [9920419.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):47-57 [9921973.001]
  • [Cites] Prostate. 1999 Jun 15;40(1):14-9 [10344719.001]
  • [Cites] J Am Coll Surg. 1999 Jul;189(1):1-7 [10401733.001]
  • [Cites] Cell Mol Life Sci. 2004 Oct;61(19-20):2614-23 [15526166.001]
  • [Cites] Neoplasia. 2004 Sep-Oct;6(5):611-22 [15548371.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1619-26 [15753353.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3218-25 [15833853.001]
  • [Cites] J Cell Biol. 2000 Feb 21;148(4):665-78 [10684249.001]
  • [Cites] J Cell Biol. 2001 Aug 20;154(4):775-84 [11514591.001]
  • [Cites] Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66 [11602373.001]
  • [Cites] Am J Pathol. 2003 Apr;162(4):1151-62 [12651607.001]
  • (PMID = 16847067.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / G0301157; United States / NIGMS NIH HHS / GM / P50 GM021681; United States / NIGMS NIH HHS / GM / P05GM21681
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Gelsolin; 0 / Microfilament Proteins; 0 / Neoplasm Proteins; 0 / Nuclear Proteins; 0 / RNA, Neoplasm; 148412-71-9 / CAPG protein, human
  • [Other-IDs] NLM/ PMC1856675
  •  go-up   go-down


73. Heyer CM, Kagel T, Lemburg SP, Walter JW, de Zeeuw J, Junker K, Mueller KM, Nicolas V, Bauer TT: Transbronchial biopsy guided by low-dose MDCT: a new approach for assessment of solitary pulmonary nodules. AJR Am J Roentgenol; 2006 Oct;187(4):933-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • SUBJECTS AND METHODS: We included 33 consecutive patients (25 men; mean age +/- SD, 64 +/- 9.6 years) with solitary pulmonary nodules at different sites and with a lesion-to-pleura distance of at least 2 cm who previously underwent conventional bronchoscopy that did not result in histologic diagnosis.
  • RESULTS: The diagnostic yield was 24 in 33 selected patients (overall accuracy, 72.7%): 13 (54%) had primary lung cancer and 11 (46%) had benign diagnoses.
  • The final diagnoses of the remaining nine patients in whom transbronchial bronchoscopic biopsy was not diagnostic were non-small cell lung cancer (n = 3); small cell lung cancer (n = 3); and alveolar carcinoma, carcinoid tumor, and hemorrhaged bulla (n = 1 each).
  • [MeSH-major] Biopsy, Needle / methods. Lung / pathology. Lung Neoplasms / diagnosis. Radiography, Interventional. Solitary Pulmonary Nodule / diagnosis. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16985137.001).
  • [ISSN] 1546-3141
  • [Journal-full-title] AJR. American journal of roentgenology
  • [ISO-abbreviation] AJR Am J Roentgenol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Gangi A, Basile A, Buy X, Alizadeh H, Sauer B, Bierry G: Radiofrequency and laser ablation of spinal lesions. Semin Ultrasound CT MR; 2005 Apr;26(2):89-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor ablation guided with medical imaging proved a high local efficacy over 90% for tumors less than 25 mm in the liver, lung, and kidney.
  • First, the tumor ablation is reviewed with malignant and benign tumors.
  • In malignant tumors, radiofrequency is very efficient in local tumor control and in pain management.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Semin Ultrasound CT MR. 2005 Oct;26(5):304. Basille, A [corrected to Basile, A]
  • (PMID = 15856810.001).
  • [ISSN] 0887-2171
  • [Journal-full-title] Seminars in ultrasound, CT, and MR
  • [ISO-abbreviation] Semin. Ultrasound CT MR
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 51
  •  go-up   go-down


75. Chen G, Liu XY, Wang Z, Liu FY: Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg; 2010 Mar;37(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer.
  • OBJECTIVE: Mediastinal lymph node metastasis (N2) is a key prognostic factor for lung carcinoma.
  • This study was undertaken to investigate the relationship between vascular endothelial growth factor C (VEGF-C) expression and postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • METHODS: Cancer tissue samples from 92 patients with pN2 non-small-cell lung cancer and benign lung disease tissues samples from 30 patients were examined by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry assays to detect VEGF-C expression.
  • All patients with N2 disease were evaluated within 1 year after surgery to detect early tumour recurrence.
  • Cox regression analysis was performed to determine the risk factors of postoperative early recurrence of N2 lung cancer.
  • RESULTS: VEGF-C mRNA expression was observed in 64 (70%) pN2 lung cancer tissues, but was not found in benign lung disease tissues.
  • The main pattern was distant recurrence, and the most frequent sites were the brain and lung.
  • Cox regression analysis revealed that positive VEGF-C expression in tumours (hazard ratio (HR)=2.523, P=0.037) was an independent risk factor of postoperative early recurrence of N2 lung cancer.
  • CONCLUSIONS: VEGF-C expression was high in N2 lung cancer, with significant correlation to postoperative early recurrence.
  • About one-half of the patients with N2 non-small-cell lung cancer would develop recurrence disease within 1 year after surgery, frequently with mediastinal nodes, brain or lung metastases.
  • VEGF-C might be a predictor of postoperative early recurrence in patients with N2 non-small-cell lung cancer.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19758816.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


76. Peng Z, Shan C, Wang H: [Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers]. Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2010 Mar;35(3):247-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Value of promoter methylation of RASSF1A, p16, and DAPK genes in induced sputum in diagnosing lung cancers].
  • OBJECTIVE: To determine the aberrant methylation status of RASSF1A,p16 and DAPK gene promoter region in induced sputum from lung cancer patients and the value of their combined detection in diagnosing lung cancers.
  • METHODS: Methylation-specific PCR (MSP) was used to detect the promoter methylation status of RASSF1A, p16, and DAPK genes in induced sputum and pathological tissues from 82 patients with lung cancers and 25 patients with pulmonary benign lesion.
  • RESULTS: The positive rates of promoter methylation of RASSF1A, p16, and DAPK genes in pathological tissues from patients with lung cancers were 63.4%, 59.8%, and 58.5%, respectively,and those in induced sputum were 54.9%, 48.8%, and 51.2%, respectively.
  • The promoter methylation of RASSF1A,p16, and DAPK genes were not detected in patients with pulmonary benign lesion.
  • There was a significant difference between the lung cancer group and pulmonary benign lesion group (P<0.05).
  • The methylation rate of RASSF1A gene was significantly lower in the middle and high differentiation and non-metastastic lymph node of lung cancer tissues than that in the poor differentiation and the metastatic lymph node of lung cancer tissues(P<0.05), and was not correlated with age, sex, smoking index, clinical stage, and pathological types.The methylation rate of p16, and DAPK genes was not significantly correlated with all the above mentioned factors (P>0.05).
  • CONCLUSION: Joint detection for promoter hypermethylation of RASSF1A, p16, and DAPK genes in induced sputum may be used as a simple and effective index of the diagnosis and prognose of lung cancers, and can improve the positive rate.
  • [MeSH-major] Apoptosis Regulatory Proteins / genetics. Calcium-Calmodulin-Dependent Protein Kinases / genetics. Cyclin-Dependent Kinase Inhibitor p16 / genetics. Lung Neoplasms / diagnosis. Sputum / metabolism. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / genetics. Aged. Carcinoma, Squamous Cell / diagnosis. Carcinoma, Squamous Cell / genetics. DNA Methylation. Death-Associated Protein Kinases. Female. Humans. Male. Middle Aged. Polymerase Chain Reaction / methods. Promoter Regions, Genetic / genetics

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20360646.001).
  • [ISSN] 1672-7347
  • [Journal-full-title] Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences
  • [ISO-abbreviation] Zhong Nan Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / RASSF1 protein, human; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / Death-Associated Protein Kinases; EC 2.7.11.17 / Calcium-Calmodulin-Dependent Protein Kinases
  •  go-up   go-down


77. Harrison-Phipps KM, Nichols FC, Schleck CD, Deschamps C, Cassivi SD, Schipper PH, Allen MS, Wigle DA, Pairolero PC: Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis. J Thorac Cardiovasc Surg; 2009 Jul;138(1):19-25
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumors of the pleura: results of surgical treatment and long-term prognosis.
  • OBJECTIVE: We sought to define the long-term outcome of surgically treated solitary fibrous tumors of the pleura.
  • Tumors were polypoid in 57 patients, sessile in 20 patients, and intrapulmonary in 7 patients.
  • Histopathology was benign in 73 and malignant in 11 patients.
  • Nine (82%) patient with malignant tumors and 37 (54%) patients with benign tumors were symptomatic (P = .11).
  • The median tumor diameters for malignant and benign tumors were 12.0 and 4.5 cm, respectively (P = .001).
  • Median survival for patients with benign and malignant tumors was 284 and 55 months, respectively, and 5-year survival was 88.9% and 45.5%, respectively (P = .0005).
  • Eight (9.5%) patients had recurrent solitary fibrous tumors of the pleura.
  • Recurrences were malignant in 6 and benign in 2 patients.
  • CONCLUSION: Resection of benign solitary fibrous tumors of the pleura carries an excellent prognosis.
  • Larger tumors are more likely to be malignant.
  • Both benign and malignant tumors can recur.
  • Although prolonged survival after resection of malignant tumors is possible, recurrence is common.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Thorac Surg. 2005 Jan;79(1):303-7 [15620963.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Ann Thorac Surg. 1999 May;67(5):1456-9 [10355431.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] J Thorac Cardiovasc Surg. 1978 Mar;75(3):363-72 [633933.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Histopathology. 1997 Dec;31(6):568-76 [9447390.001]
  • [Cites] J Thorac Surg. 1952 Sep;24(3):213-30 [13000916.001]
  • [Cites] Clin Lung Cancer. 2005 Nov;7(3):197-201 [16354315.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • (PMID = 19577049.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA090628-09; United States / NCI NIH HHS / CA / K12 CA090628; United States / NCI NIH HHS / CA / K12 CA090628-09
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS217187; NLM/ PMC2930758
  •  go-up   go-down


78. Ai ZH, Zhang WX, Luo WJ, Huang LJ, Pan Y: [Expression and significance of Pin1 mRNA in circulating mononuclear cells from non-small cell lung cancer patients during perioperative period]. Ai Zheng; 2009 Mar;28(3):268-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression and significance of Pin1 mRNA in circulating mononuclear cells from non-small cell lung cancer patients during perioperative period].
  • This study was to detect the expression of Pin1 mRNA in blood samples from non-small cell lung cancer (NSCLC) patients, and explore its significance.
  • Additionally, ten patients with benign lung disease who underwent resection served as disease control, and ten healthy subjects served as negative control.
  • RESULTS: The mRNA level of Pin1 was obviously higher in blood samples from NSCLC patients than in those from benign lung disease patients and healthy subjects: it in NSCLC group was 1.69-34.78 times of that in negative control group.
  • CONCLUSION: Pin1 is overexpressed in circulation of NSCLC, and may be used as a tumor marker or as a target for cancer therapy.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / blood. Lung Neoplasms / blood. Peptidylprolyl Isomerase / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / analysis. Female. Humans. Ligation / methods. Lung Diseases / blood. Lung Diseases / surgery. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Perioperative Period. Pulmonary Artery / surgery. Pulmonary Veins / surgery. RNA, Messenger / blood. Smoking

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619441.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / NIMA-interacting peptidylprolyl isomerase; 0 / RNA, Messenger; EC 5.2.1.8 / Peptidylprolyl Isomerase
  •  go-up   go-down


79. Chen M, Chen LM, Lin CY, Chai KX: The epidermal growth factor receptor (EGFR) is proteolytically modified by the Matriptase-Prostasin serine protease cascade in cultured epithelial cells. Biochim Biophys Acta; 2008 May;1783(5):896-903
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The EGFR ECD proteolytic modification by matriptase-prostasin is also observed in the BEAS-2B normal lung epithelial cells, the BPH-1 benign prostate hyperplasia and the MDA-MB-231 breast cancer cell lines; and represents a novel mechanism for epithelial cells to modulate EGF-EGFR signaling.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Soc Nephrol. 2000 May;11(5):828-34 [10770960.001]
  • [Cites] Histol Histopathol. 2007 Apr;22(4):349-63 [17290345.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37 [11252954.001]
  • [Cites] Biochem J. 2001 May 15;356(Pt 1):87-96 [11336639.001]
  • [Cites] J Am Soc Nephrol. 2001 Jun;12(6):1114-21 [11373334.001]
  • [Cites] J Biol Chem. 2001 Jun 15;276(24):21434-42 [11274175.001]
  • [Cites] Prostate. 2001 Jul 1;48(2):93-103 [11433419.001]
  • [Cites] J Natl Cancer Inst. 2001 Oct 3;93(19):1458-64 [11584061.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S9-15 [11597399.001]
  • [Cites] Eur J Cancer. 2001 Sep;37 Suppl 4:S16-22 [11597400.001]
  • [Cites] Int J Cancer. 2002 Jan 20;97(3):323-9 [11774283.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Mar;282(3):C420-33 [11832327.001]
  • [Cites] J Am Soc Nephrol. 2002 Mar;13(3):588-94 [11856761.001]
  • [Cites] Prostate. 2003 Feb 15;54(3):187-93 [12518323.001]
  • [Cites] Cancer Res. 2003 Mar 1;63(5):1101-5 [12615728.001]
  • [Cites] Prostate. 2004 Apr 1;59(1):1-12 [14991861.001]
  • [Cites] Oncogene. 2004 Jun 3;23(26):4594-602 [15077177.001]
  • [Cites] J Invest Dermatol. 2004 Nov;123(5):982-9 [15482488.001]
  • [Cites] J Urol. 1990 Jun;143(6):1272-4 [1692888.001]
  • [Cites] Mol Cell Biochem. 1993 Sep 22;126(2):151-8 [7508078.001]
  • [Cites] J Cell Physiol. 1995 Mar;162(3):434-46 [7860650.001]
  • [Cites] J Biol Chem. 1995 Jun 2;270(22):13483-9 [7768952.001]
  • [Cites] Nature. 1997 Oct 9;389(6651):607-10 [9335501.001]
  • [Cites] Dan Med Bull. 1998 Apr;45(2):121-34 [9587699.001]
  • [Cites] Int J Biochem Cell Biol. 1999 Jun;31(6):637-43 [10404636.001]
  • [Cites] Neoplasia. 2004 Nov-Dec;6(6):846-53 [15720812.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Aug;289(2):C462-70 [15800053.001]
  • [Cites] APMIS. 2005 May;113(5):332-9 [16011659.001]
  • [Cites] J Cell Biol. 2005 Aug 1;170(3):487-96 [16061697.001]
  • [Cites] J Biol Chem. 2005 Oct 14;280(41):34513-20 [16103126.001]
  • [Cites] Gene. 2006 Jan 17;366(1):2-16 [16377102.001]
  • [Cites] APMIS. 2006 Jan;114(1):61-6 [16499663.001]
  • [Cites] Breast Cancer Res Treat. 2006 Feb;95(3):211-8 [16261406.001]
  • [Cites] Prostate. 2006 Jun 15;66(9):911-20 [16541421.001]
  • [Cites] Mol Genet Metab. 2006 Jun;88(2):114-22 [16487738.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Aug 11;346(4):1245-53 [16806080.001]
  • [Cites] Am J Physiol Renal Physiol. 2006 Sep;291(3):F567-77 [16638913.001]
  • [Cites] Br J Cancer. 2007 Apr 23;96(8):1246-52 [17406365.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7570-5 [17456594.001]
  • [Cites] Int J Biol Markers. 2007 Jan-Mar;22(1 Suppl 4):S71-6 [17520584.001]
  • [Cites] Biochim Biophys Acta. 2007 Jul;1773(7):1133-40 [17532063.001]
  • [Cites] Recent Results Cancer Res. 2007;176:135-43 [17607921.001]
  • [Cites] Cell Prolif. 2007 Aug;40(4):580-94 [17635524.001]
  • [Cites] J Cell Physiol. 2007 Oct;213(1):237-45 [17471493.001]
  • [Cites] Respirology. 2006 Nov;11(6):687-92 [17052295.001]
  • [Cites] J Biol Chem. 2006 Nov 3;281(44):32941-5 [16980306.001]
  • [Cites] Histol Histopathol. 2007 Mar;22(3):305-9 [17163404.001]
  • [Cites] Mol Cell Biol. 2007 Feb;27(3):888-98 [17101784.001]
  • [Cites] J Mol Endocrinol. 2007 Feb;38(1-2):51-66 [17242169.001]
  • [Cites] Bioessays. 2000 Aug;22(8):697-707 [10918300.001]
  • (PMID = 18054338.001).
  • [ISSN] 0006-3002
  • [Journal-full-title] Biochimica et biophysica acta
  • [ISO-abbreviation] Biochim. Biophys. Acta
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA 096854; United States / NCI NIH HHS / CA / CA104944-04; United States / NCI NIH HHS / CA / R01 CA096851-05; United States / NCI NIH HHS / CA / R01 CA096851; United States / NCI NIH HHS / CA / CA096851-05; United States / NCI NIH HHS / CA / R01 CA 104944; United States / NCI NIH HHS / CA / R01 CA104944; United States / NCI NIH HHS / CA / R01 CA104944-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 42HK56048U / Tyrosine; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.4.21.- / Serine Endopeptidases; EC 3.4.21.- / matriptase; EC 3.4.21.- / prostasin
  • [Other-IDs] NLM/ NIHMS48494; NLM/ PMC3214967
  •  go-up   go-down


80. Smith CJ, Perfetti TA, King JA: Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers. Inhal Toxicol; 2006 Aug;18(9):667-77
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Perspectives on pulmonary inflammation and lung cancer risk in cigarette smokers.
  • The particulate phase is mutagenic and cytotoxic in vitro, proinflammatory, and promotes tumor formation in animal models.
  • A large body of evidence suggests that smoking-induced pulmonary inflammation may play an important role in increasing lung cancer risk in smokers.
  • Use of aspirin and nonsteroidal anti-inflammatory drugs is associated with reduced cancer development in animal models and lower lung cancer rates in smokers.
  • A number of benign nonpulmonary and pulmonary diseases characterized by chronic inflammation increase the risk of cancer at the affected site in the absence of chemical exposure.
  • A relationship between pulmonary inflammation and lung cancer is mechanistically plausible because inflammatory cells secrete activated oxygen species, inflammatory mediators, and proteolytic enzymes that can both damage DNA and lead to increases in reparative cell proliferation rates.
  • [MeSH-major] Inflammation / etiology. Lung Neoplasms / etiology. Smoking / adverse effects. Tobacco Smoke Pollution / adverse effects


81. Cho SJ, Jin LJ, Kim BY, Cho SI, Jung WY, Han JH, Ha SY, Kim HK, Kim A: Increased expression of matrix metalloproteinase 9 and tubulin-alpha in pulmonary sclerosing hemangioma. Oncol Rep; 2007 Nov;18(5):1139-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pulmonary sclerosing hemangioma (PSH) is relatively rare and is usually considered a benign tumor because of its slow growth and solitary characteristics.
  • Three sets of PSH specimens from the Korea Lung Tissue Bank, obtained with IRB approval, were analyzed through the construction of an oligo-microarray that contained about 32,000 genes.
  • In the 3 specimens of PSH tissues, 72 of the 32,000 genes were commonly found up-regulated and 290 were commonly found down-regulated as compared to non-tumor tissues from each patient.
  • Paraffin-embedded tissues from 11 cases were used to confirm the expression of matrix metalloproteinase 9 (MMP-9) and tubulin-alpha proteins in the non-tumor and PSH tissues via IHC.
  • As expected, in all cases MMP-9 and tubulin-alpha were expressed at significantly higher levels in the PSH than in the non-tumor tissues.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Gene Expression Profiling. Matrix Metalloproteinase 9 / metabolism. Pulmonary Sclerosing Hemangioma / enzymology. Tubulin / metabolism

  • Genetic Alliance. consumer health - Hemangioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17914564.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / Tubulin; EC 3.4.24.35 / Matrix Metalloproteinase 9
  •  go-up   go-down


82. Rodriguez FJ, Aubry MC, Tazelaar HD, Slezak J, Carney JA: Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma. Am J Surg Pathol; 2007 Dec;31(12):1844-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary chondroma: a tumor associated with Carney triad and different from pulmonary hamartoma.
  • The Carney triad is the clinical association of gastric stromal sarcomas, pulmonary cartilaginous tumors, and extra-adrenal paragangliomas.
  • The pulmonary tumors are its second commonest component and have been misinterpreted clinically and pathologically as metastases from the gastric tumors and pulmonary cartilaginous hamartomas, respectively.
  • Forty-two patients with pulmonary cartilaginous tumors as a component of Carney triad were identified.
  • A subgroup of 41 tumors from the latter was compared with those in a group of pulmonary cartilaginous hamartomas.
  • Their pulmonary neoplasm(s) were usually asymptomatic, often multiple, well circumscribed, medium-sized (mean diameter=2.8 cm), and composed almost exclusively of cartilage and bone surrounded by a fibrous pseudocapsule.
  • None of the tumors metastasized or was fatal.
  • The pulmonary neoplasms in the Carney triad are well-differentiated benign cartilaginous tumors that are best designated as chondromas.
  • [MeSH-major] Chondroma / pathology. Hamartoma / pathology. Lung Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Gastrointestinal Stromal Tumors / pathology. Humans. Male. Middle Aged. Paraganglioma, Extra-Adrenal / pathology

  • Genetic Alliance. consumer health - Chondroma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18043038.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


83. Kisselbach C, Ristic AD, Pankuweit S, Karatolius K, Maisch B: [Women and pericardial neoplastic manifestations of the heart and pericardium]. Herz; 2005 Aug;30(5):409-15; quiz 429-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Data on epidemiology and incidence are rare: there is only an estimated incidence of cardiac neoplasm at necropsy ranging from 0,001% to 0,3%.
  • The majority of the primary tumors are benign.
  • The most common tumor entity is benign cardiac myxoma.
  • Malignant heart tumors are less common.
  • Metastatic tumors of the heart are 100 times more common than the primary ones.
  • They originate mainly from melanomas, leukemias, lymphomas, and cancer, especially of the lung or breast.
  • Indeed in women breast cancer is the most common metastatic tumor associated with pericardial effusion.
  • However, more of the malignant tumors may be curable if exactly diagnosed at an earlier stage.
  • METHODS: A retrospective study was conducted of all patients with cardiac and pericardial neoplasm exactly diagnosed by endomyocardial or epicardial biopsy and pericardiocentesis, using hospital medical records and a biopsy and pericardiocentesis registry from 2000-2005 with 297 patients.
  • RESULTS: In 76 cases (25.6%) a neoplasm was the reason for a pericardial effusion.
  • 36 women suffered from the breast carcinoma (47%) and 40 males lung cancer (42%) as the firstly metastatic tumor.
  • CONCLUSION: Females are more often affected by primary cardiac tumors than males with an excellent outcome.
  • By contrast, the preventive checkup and aftercare will gain more prognostic importance, especially in case of breast cancer, to earlier recognize a secondary cardiac neoplasm by biopsy and pericardiocentesis with intrapericardial treatment of neoplastic pericarditis.
  • [MeSH-major] Breast Neoplasms / epidemiology. Breast Neoplasms / secondary. Heart Neoplasms / epidemiology. Heart Neoplasms / secondary. Lung Neoplasms / epidemiology. Lung Neoplasms / secondary. Registries. Risk Assessment / methods

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16132244.001).
  • [ISSN] 0340-9937
  • [Journal-full-title] Herz
  • [ISO-abbreviation] Herz
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


84. Rai SP, Patil AP, Saxena P, Kaur A: Laser resection of endobronchial hamartoma via fiberoptic bronchoscopy. Lung India; 2010 Jul;27(3):170-2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Endobronchial hamartoma is a rare benign tumor of lung that may present with symptoms of airway obstruction with wheezing, stridor, recurrent pneumonia or atelectasis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20931040.001).
  • [ISSN] 0974-598X
  • [Journal-full-title] Lung India : official organ of Indian Chest Society
  • [ISO-abbreviation] Lung India
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2946723
  • [Keywords] NOTNLM ; Diode laser / endobronchial hamartoma / fiberoptic bronchoscope / laser resection
  •  go-up   go-down


85. Zhang XM, Shen CY, Li W, Zhang XM: [Surgical treatment of tumor invading important vessel]. Zhonghua Wai Ke Za Zhi; 2007 Aug 1;45(15):1044-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Surgical treatment of tumor invading important vessel].
  • OBJECTIVE: To sum up preliminary experience of successful resection of tumor involving important vessel in 77 cases.
  • The tumor involving thoraco-abdominal cavity was in one case with malignant neuroblastoma.
  • The tumor from retro-peritoneum invaded into the whole inferior vena cava (IVC), and into two-thirds of the right atrium.
  • Tumor located in thoracic cavity were in 13 cases including IVC leiomyosarcoma in 2 cases, thymic carcinoma in 3 cases, malignant thymoma in 4 cases, malignant seminoma of superior mediastinum in 1 case, malignant lymphoma in 1 case, lung cancer in 2 cases.
  • The tumor located in abdominal cavity were in 24 cases including renal carcinoma with tumor thrombi in 11 cases, inflammatory pseudotumor of retro-peritoneum in 4 cases, malignant fibrous histiocytoma of retro-peritoneum in 1 case, non-Hodgkin's disease of retro-peritoneum in 1 case, lymph metastasis of retro-peritoneum in 2 cases, paraganglion tumor of the right adrenal gland in 1 case, ampullary carcinoma in 1 case, leiomyosarcoma of abdominal IVC in 1 case, leiomyosarcoma of pelvic cavity and IVC in 1 cases, fibrosarcoma of pelvic cavity in 1 case.
  • Tumor located in four extremities in 6 cases including osteogenic sarcoma in 3 cases, vascular endotheliosarcoma of the left iliac fossa in 1 case, neurofibroma of the left upper extremity in 1 case, lymphoma of double groin in 1 case.
  • Tumor located in neck in 33 cases including carotid body tumor in 32 cases and neurofibroma of the left upper extremity in 1 case.
  • RESULTS: Complete resection of tumor was in 72 cases, with a rate of 93.5%, palliative resection of tumor was in 5 cases with a rate of 6.5%.
  • Temporary shunt of carotid artery for neck tumor was used in 18 cases.
  • No death occurred for benign tumor.
  • CONCLUSION: The radical resection rate for tumor involving important vessel may be improved with the help of vascular technique.
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Invasiveness. Retrospective Studies. Treatment Outcome. Vena Cava, Inferior / pathology. Vena Cava, Inferior / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18005586.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


86. Kosacka M, Wojtala R, Piesiak P, Passowicz-Muszyńska E, Jankowska R: [A case of kappa L-chain primary nodular lung amyloidosis]. Pol Merkur Lekarski; 2008 Dec;25(150):516-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of kappa L-chain primary nodular lung amyloidosis].
  • We report a case of kappa L-chain primary lung amyloidosis.
  • The mammography revealed tumor of the breast and the metastatic breast cancer have been suspected.
  • After the quadrantectomy the breast tumor has been diagnosed as adenoma.
  • The diagnosis of pulmonary amyloidosis was established by an open lung biopsy.
  • The case illustrates the problems with diagnosis of multiple solitary nodules and the long and relatively benign course of primary pulmonary amyloidosis.
  • [MeSH-major] Amyloid / metabolism. Amyloidosis / diagnosis. Amyloidosis / metabolism. Immunoglobulin kappa-Chains / metabolism. Solitary Pulmonary Nodule / diagnosis. Solitary Pulmonary Nodule / metabolism
  • [MeSH-minor] Adult. Biomarkers / metabolism. Biopsy. Diagnosis, Differential. Female. Humans. Lung Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Amyloidosis.
  • MedlinePlus Health Information. consumer health - Amyloidosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19205385.001).
  • [ISSN] 1426-9686
  • [Journal-full-title] Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego
  • [ISO-abbreviation] Pol. Merkur. Lekarski
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Amyloid; 0 / Biomarkers; 0 / Immunoglobulin kappa-Chains
  •  go-up   go-down


87. Paci M, Cavazza A, Annessi V, Ricchetti T, Rapicetta C, Sgarbi G: Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion. Rare Tumors; 2010;2(1):e14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cystic fibrohistiocytic tumor of the lung presenting as a solitary lesion.
  • Cystic fibrohistiocytic tumor of the lung is a rare neoplasm.
  • In many cases it represents a metastasis from a benign or low-grade fibrohistiocytic tumor of the skin, but occasionally it may be primary.
  • Microscopy of the apical segmentectomy showed a cystic fibrohistiocytic tumor, whereas the nodule of the lower lobe was an intraparenchymal lymph node.
  • The patient is alive with no tumor recurrence.
  • The differential diagnosis includes Langerhans cell histiocytosis, lymphangioleiomyomatosis, pleuropulmonary blastoma, and metastatic endometrial stromal sarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21139943.001).
  • [ISSN] 2036-3613
  • [Journal-full-title] Rare tumors
  • [ISO-abbreviation] Rare Tumors
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Other-IDs] NLM/ PMC2994490
  • [Keywords] NOTNLM ; cystic fibrohistiocytic tumor / lung neoplasms / mesenchymal cystic hamartoma / mesenchymal tumors / metastases / pneumothorax
  •  go-up   go-down


88. Schmiemann V, Böcking A, Kazimirek M, Onofre AS, Gabbert HE, Kappes R, Gerharz CD, Grote HJ: Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study. Clin Cancer Res; 2005 Nov 1;11(21):7728-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Methylation assay for the diagnosis of lung cancer on bronchial aspirates: a cohort study.
  • PURPOSE: Recent studies have detected aberrant promoter methylation of adenomatous polyposis coli promoter 1 A (APC), cyclin-dependent kinase inhibitor-2A (p16(INK4a)), retinoic acid receptor beta2, and RAS association domain family protein 1 (RASSF1A) in bronchial aspirates and suggested their use as biomarkers for lung cancer diagnostics.
  • EXPERIMENTAL DESIGN: Bronchial aspirates collected from a cohort comprising 247 patients with suspected lung cancer were investigated retrospectively regarding aberrant promoter methylation using a quantitative methylation-specific real-time PCR (QMSP).
  • RESULTS: Eighty-nine patients were diagnosed with primary lung cancer, 102 had benign lung disease, and 56 showed miscellaneous other conditions.
  • This panel detected aberrant methylation in bronchial aspirates of 22 of 35 (63%) and 21 of 44 (44%) centrally and peripherally located primary lung cancers, respectively.
  • Bronchial aspirates also showed aberrant methylation in 5 of 7 (71%) patients with a recurrent lung cancer and in 8 of 30 (27%) cases without tumor recurrence.
  • In contrast, only 1 of 102 patients with benign lung disease displayed a (false) positive test result.
  • The QMSP assay correctly confirmed lung cancer in 8 of 12 (67%) cases with an ambiguous cytology.
  • Moreover, it disclosed 9 of 26 (35%) of peripheral tumors lacking simultaneous cytologic or histologic diagnosis of malignancy.
  • CONCLUSIONS: Our findings suggest that the QMSP assay could be applied as a reflex test in cases of suspected lung cancer that defy a definite diagnosis by conventional methods.
  • Thus, the assay could be a useful diagnostic adjunct especially regarding peripheral tumors.
  • [MeSH-major] Bronchi / metabolism. DNA Methylation. Lung Neoplasms / diagnosis. Lung Neoplasms / genetics
  • [MeSH-minor] Adenomatous Polyposis Coli Protein / metabolism. Adult. Aged. Aged, 80 and over. Biopsy. Bronchoscopy. Case-Control Studies. Cell Line, Tumor. Cohort Studies. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. DNA Primers / chemistry. False Positive Reactions. Female. Humans. Lung / pathology. Male. Middle Aged. Polymerase Chain Reaction. Receptors, Retinoic Acid / metabolism. Retrospective Studies. Reverse Transcriptase Polymerase Chain Reaction. Sulfites / pharmacology. Temperature. Tumor Suppressor Proteins / genetics

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16278393.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adenomatous Polyposis Coli Protein; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / DNA Primers; 0 / RASSF1 protein, human; 0 / Receptors, Retinoic Acid; 0 / Sulfites; 0 / Tumor Suppressor Proteins; 0 / retinoic acid receptor beta
  •  go-up   go-down


89. Zhang PJ, Gao HG, Pasha TL, Litzky L, Livolsi VA: TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems. Int J Gynecol Pathol; 2009 Jan;28(1):10-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] TTF-1 expression in ovarian and uterine epithelial neoplasia and its potential significance, an immunohistochemical assessment with multiple monoclonal antibodies and different secondary detection systems.
  • Thyroid transcription factor-1 (TTF-1) is a 38-kd homeodomain containing DNA-binding protein, identified in thyroid and lung as a regulator of thyroid-specific genes and surfactant and Clara cell secretory protein gene expression.
  • TTF-1 has been used as a reliable lineage marker for lung adenocarcinoma and thyroid carcinoma in surgical pathology.
  • We evaluated TTF-1 expression with 3 primary different antibodies (8G7G3/1, SPT24, and BGX-397A) and 2 secondary automated detection systems (Envision+/Dako autostainer versus Refine/Bond Max) in 104 ovarian and endometrial tumors on routine surgical specimens and 108 ovarian tumors on tissue microarray (TMA) specimens.
  • By using SPT24/Refine/Bond Max, TTF-1 reactivity could be detected in all major histologic subtypes of gynecologic tumors and up to 26% of all cases tested on routine surgical specimens and 6.4% on TMA.
  • TTF-1 was most frequently detected in uterine malignant mixed Müllerian tumor (82%), more common in uterine tumors than ovarian tumors, and more common in surgical specimen than TMA.
  • When present, tumor cells can be rarely positive or diffusely positive for TTF-1 reactivity.
  • In addition to malignant tumors, TTF-1 was also detected in benign tumors and benign tubal and endometrial epithelia.
  • TTF 1 immunostaining has the potential to misguide a pathologist to conclude an ovarian or endometrial tumor being a lung metastasis.
  • However, the role of TTF-1 in female genital tract and its tumors is unknown.
  • [MeSH-major] Biomarkers, Tumor / analysis. Endometrial Neoplasms / metabolism. Immunohistochemistry / methods. Nuclear Proteins / biosynthesis. Ovarian Neoplasms / metabolism. Transcription Factors / biosynthesis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19047914.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Biomarkers, Tumor; 0 / Nuclear Proteins; 0 / Transcription Factors; 0 / thyroid nuclear factor 1
  •  go-up   go-down


90. Hara R, Matsuguma H, Suzuki H, Ishikawa Y, Nakahara R, Yamaguchi T, Hirabayashi K: Desmoid tumor presenting as a superior sulcus tumor: a unique bone change in the vertebral body. Ann Thorac Surg; 2007 Nov;84(5):1752-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Desmoid tumor presenting as a superior sulcus tumor: a unique bone change in the vertebral body.
  • Desmoid tumor, also referred to as aggressive fibromatosis, is a relatively rare, locally infiltrative, histologically benign tumor.
  • This report details a case of desmoid tumor presented as a superior sulcus tumor, which showed a unique manifestation in the vertebral bodies on computed tomography.
  • [MeSH-major] Fibromatosis, Aggressive / pathology. Lung Neoplasms / pathology. Spine / pathology

  • Genetic Alliance. consumer health - Desmoid Tumor.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17954107.001).
  • [ISSN] 1552-6259
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


91. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Lung and intraabdominal organs are most frequently affected.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Advice from a second pathologist was seeked, who suggested the diagnosis of intraosseous meningioma.
  • Workup studies failed to reveal any primary tumor.
  • In May 2004 the patient was admitted to our department and a new transpedicular biopsy confirmed the diagnosis.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


92. Iglesias-Garcia J, Larino-Noia J, Abdulkader I, Forteza J, Dominguez-Munoz JE: Quantitative endoscopic ultrasound elastography: an accurate method for the differentiation of solid pancreatic masses. Gastroenterology; 2010 Oct;139(4):1172-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND & AIMS: Qualitative endoscopic ultrasound (EUS) elastography is an accurate but subjective tool for the differential diagnosis of solid pancreatic masses.
  • We evaluated the accuracy of quantitative, second-generation EUS elastography in the differential diagnosis of solid pancreatic masses.
  • Final diagnosis was based on histology of surgical specimens and cytology of EUS-fine-needle aspiration samples.
  • The final diagnoses were pancreatic adenocarcinoma (n = 49), inflammatory mass (n = 27), malignant neuroendocrine tumor (n = 6), metastatic oat-cell lung cancer (n = 2), pancreatic lymphoma (n = 1), and pancreatic solid pseudopapillary tumor (n = 1).
  • The strain ratio was significantly higher among patients with pancreatic malignant tumors compared with those with inflammatory masses.
  • CONCLUSIONS: Quantitative, second-generation EUS elastography is useful for differential diagnosis of solid pancreatic masses.
  • It allows for a quantitative and objective evaluation of tissue stiffness, which indicates the malignant or benign nature of the pancreatic lesion.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 AGA Institute. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20600020.001).
  • [ISSN] 1528-0012
  • [Journal-full-title] Gastroenterology
  • [ISO-abbreviation] Gastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


93. Wang H, Jiang G, Wang D, Liu J, Wang J: [mRNA expression of MAGE genes in benign and malignant pleural effusion]. Zhongguo Fei Ai Za Zhi; 2006;9(4):329-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [mRNA expression of MAGE genes in benign and malignant pleural effusion].
  • BACKGROUND: Melanoma antigen genes (MAGE) are tumor specific genes.
  • METHODS: The expression of MAGE-1, -2, -3 and -4 mRNA was detected in 18 benign and 22 malignant pleural effusion samples by RT-PCR.
  • RESULTS: No MAGE gene expressed in the 18 cases of benign pleural effusion.
  • CONCLUSIONS: Detection of MAGE genes in pleural effusion may be an effective method in the differential diagnosis of benign and malignant pleural effusion.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21176448.001).
  • [ISSN] 1009-3419
  • [Journal-full-title] Zhongguo fei ai za zhi = Chinese journal of lung cancer
  • [ISO-abbreviation] Zhongguo Fei Ai Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


94. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE: The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res; 2005 Feb 1;65(3):692-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we analyzed such expression in more detail and show that cyclin E is overexpressed and present in low molecular weight (LMW) isoforms in metastatic melanoma and in a subset of primary invasive melanoma tumor tissues, but not in benign nevi.
  • The biological significance of these findings was established by showing that overexpression of two LMW cyclin E forms named cyclin E truncated 1 [cyclinE(T1)] and cyclin E truncated 2 [cyclinE(T2)] in a low tumorigenic and non-metastatic primary cutaneous melanoma cell line generated angiogenic tumors with prominent perineural invasion compared with full-length cyclin E.
  • In addition, cyclin E(T1)- and cyclin E(T2)-expressing melanoma cells displayed a dramatic increase in the incidence and number of metastases in an experimental lung metastasis assay.
  • Together, these results indicate that the LMW cyclin E forms are functional and likely act as regulators of human melanoma tumor progression and invasion.
  • [MeSH-minor] Animals. Blotting, Western. CDC2-CDC28 Kinases / metabolism. Cell Cycle Proteins / metabolism. Cyclin-Dependent Kinase 2. Cyclin-Dependent Kinase Inhibitor p21. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Molecular Weight. Neoplasm Metastasis. Neoplasm Transplantation. Neovascularization, Pathologic / metabolism. Protein Isoforms. Transfection. Transplantation, Heterologous

  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15705861.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CDKN1A protein, human; 0 / Cdkn1a protein, mouse; 0 / Cell Cycle Proteins; 0 / Cyclin E; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Protein Isoforms; EC 2.7.11.22 / CDC2-CDC28 Kinases; EC 2.7.11.22 / CDK2 protein, human; EC 2.7.11.22 / Cdk2 protein, mouse; EC 2.7.11.22 / Cyclin-Dependent Kinase 2
  •  go-up   go-down


95. Molina R, Augé JM, Bosch X, Escudero JM, Viñolas N, Marrades R, Ramírez J, Carcereny E, Filella X: Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol; 2009;30(3):121-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of serum tumor markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology.
  • BACKGROUND: Tumor markers have been extensively studied in lung cancer, reporting some relationship to the histology, but their clinical utility is not clear.
  • METHODS: ProGRP, CEA, SCC, CA 125, CYFRA 21-1 and NSE were studied prospectively in 155 patients with unconfirmed suspicion of lung cancer and in 647 patients with lung cancer: 182 squamous, 205 adenocarcinomas, 19 large-cell lung cancer (LCLC), 175 small-cell lung cancer (SCLC) and 66 unspecific non-small-cell lung cancer (NSCLC).
  • RESULTS: Abnormal tumor marker serum levels were found in less than 5.3% of the patients with benign diseases, excluding CA 125 (21.3%).
  • Tumor markers were related to histological type and tumor extension with significantly higher CEA (p <0.01) and CA 125 (p <0.007) serum levels in adenocarcinomas, SCC (p <0.0001) and CYFRA 21-1 (p <0.008) in squamous tumors and ProGRP (p <0.0001) and NSE (p <0.0001) in SCLC.
  • Tumor markers may be useful in the histological differentiation of NSCLC and SCLC.
  • CONCLUSIONS: Tumor marker determination in patients with suspicious signs of lung cancer suggests, in a few hours, the histological diagnosis in the majority of lung cancer patients.
  • [MeSH-major] Biomarkers, Tumor / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Squamous Cell / blood. Lung Neoplasms / blood. Peptide Fragments / blood. Small Cell Lung Carcinoma / blood
  • [MeSH-minor] Algorithms. Enzyme-Linked Immunosorbent Assay. Female. Humans. Male. Middle Aged. Neoplasm Staging. Recombinant Proteins / blood. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19506400.001).
  • [ISSN] 1423-0380
  • [Journal-full-title] Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
  • [ISO-abbreviation] Tumour Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Peptide Fragments; 0 / Recombinant Proteins; 0 / pro-gastrin-releasing peptide (31-98)
  •  go-up   go-down


96. Duysinx BC, Corhay JL, Hubin L, Nguyen D, Henket M, Louis R: Diagnostic value of interleukine-6, transforming growth factor-beta 1 and vascular endothelial growth factor in malignant pleural effusions. Respir Med; 2008 Dec;102(12):1708-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • STUDY OBJECTIVES: We evaluate the accuracy of pleural interleukine-6 (IL-6), transforming growth factor-beta 1 (TGF-beta1), and vascular endothelial growth factor (VEGF) levels for differentiating benign from malignant pleural exudates.
  • PATIENTS AND METHODS: Levels of IL-6, TGF-beta1, and VEGF were measured by ELISA in 103 patients with non neutrophilic (<50%) exudative pleurisy including both benign and malignant effusions.
  • Pleurisies were split into benign and malignant according to the pathological diagnosis.
  • RESULTS: Thirty-nine benign (seven infections; 32 inflammatory diseases) and 64 malignant (34 extrathoracic tumors; 25 lung cancers; five mesotheliomas) pleural exudates were diagnosed by thoracoscopy.
  • Pleural reticulo-monocyte count, protein Light's ratio and lactic dehydrogenase Light's ratio were significantly higher in malignant than in benign effusions (p<0.05, p<0.001 and p<0.001, respectively).
  • The median (range) level of VEGF was significantly higher in malignant than in benign effusions (664.50 pg/ml [10-40,143] vs 349 pg/ml [10-8888]) (p<0.05).
  • No significant difference was found between malignant and benign effusions with respect to IL-6 (26.8 ng/ml [1.8-421] vs 18.4 ng/ml [0.45-400], respectively) and TGF-beta1 (1079 pg/ml [18-6206] vs 1123 pg/ml [34-5447]) levels.
  • ROC analysis between benign and malignant pleurisies for VEGF showed an area under the curve of 619 (p=0.03) with a value of 382 pg/ml as the best threshold for distinguishing benign from malignant effusions.
  • CONCLUSIONS: Malignant effusions may enhance the release of VEGF in pleural space and its measurement may help in the diagnosis of malignant effusion.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cytokines / analysis. Pleural Effusion, Malignant / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Interleukin-6 / analysis. Male. Middle Aged. Pleural Effusion / diagnosis. Pleural Effusion / etiology. Thoracoscopy. Transforming Growth Factor beta1 / analysis. Vascular Endothelial Growth Factor A / analysis. Young Adult

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18760578.001).
  • [ISSN] 1532-3064
  • [Journal-full-title] Respiratory medicine
  • [ISO-abbreviation] Respir Med
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cytokines; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


97. García-Reyna JC, Rico Martínez G, Vega González IF, Linares LM, Delgado Cedillo EA, Romero Ramírez R: [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin]. Acta Ortop Mex; 2008 Nov-Dec;22(6):390-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Musculoskeletal tumor evaluation with 99mTc-Tetrofosmin].
  • [Transliterated title] 99mTc-Tetrofosmin en la evaluación de tumores musculoesqueléticos.
  • INTRODUCTION: (99m)Tc-tetrofosmin is an efficient agent as a tumor marker.
  • Several studies have proven its efficiency in detection and localization of tumors of the breast, larynx, thyroid, parathyroid glands, lung, brain, skin, lymphatic and musculoskeletal tissues with a sensitivity and specificity of 95% to 100%.
  • Nevertheless, benign pathology such as active inflammation is a source of false positives and the attending physician must consider the aid of complementary studies such as histopathology.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19280840.001).
  • [ISSN] 2306-4102
  • [Journal-full-title] Acta ortopédica mexicana
  • [ISO-abbreviation] Acta Ortop Mex
  • [Language] spa
  • [Publication-type] Clinical Trial; Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Mexico
  • [Chemical-registry-number] 0 / Organophosphorus Compounds; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0 / technetium Tc 99m 1,2-bis(bis(2-ethoxyethyl)phosphino)ethane
  •  go-up   go-down


98. Vargas SO, Korpershoek E, Kozakewich HP, de Krijger RR, Fletcher JA, Perez-Atayde AR: Cytogenetic and p53 profiles in congenital cystic adenomatoid malformation: insights into its relationship with pleuropulmonary blastoma. Pediatr Dev Pathol; 2006 May-Jun;9(3):190-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Congenital cystic adenomatoid malformation (CCAM), a developmental anomaly of lung, shares many features with the pediatric tumor pleuropulmonary blastoma (PPB).
  • Both may show benign epithelium-lined cysts and mesenchymal proliferation, often with skeletal muscle differentiation.
  • [MeSH-major] Cystic Adenomatoid Malformation of Lung, Congenital / genetics. Cystic Adenomatoid Malformation of Lung, Congenital / metabolism. Lung Neoplasms / genetics. Lung Neoplasms / metabolism. Pulmonary Blastoma / genetics. Pulmonary Blastoma / metabolism. Tumor Suppressor Protein p53 / metabolism
  • [MeSH-minor] Child, Preschool. Cytogenetics. DNA, Neoplasm / analysis. DNA, Neoplasm / isolation & purification. Female. Humans. Immunohistochemistry. Infant. Karyotyping. Male. Polymorphism, Single-Stranded Conformational. Prospective Studies

  • Genetic Alliance. consumer health - Pleuropulmonary blastoma.
  • Genetic Alliance. consumer health - Blastoma.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16944975.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


99. Holdenrieder S, Nagel D, Schalhorn A, Heinemann V, Wilkowski R, von Pawel J, Raith H, Feldmann K, Kremer AE, Müller S, Geiger S, Hamann GF, Seidel D, Stieber P: Clinical relevance of circulating nucleosomes in cancer. Ann N Y Acad Sci; 2008 Aug;1137:180-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here, the clinical relevance of circulating nucleosomes for diagnosis, staging, prognosis, and therapeutic monitoring of cancer is reviewed.
  • However, because of elevations of nucleosome levels in patients with benign diseases relevant for differential diagnosis, they are not suitable for cancer diagnosis.
  • Concerning tumor staging, nucleosome levels correlate with tumor stage and presence of metastases in gastrointestinal cancer, but not in other tumor types.
  • Prognostic value of circulating nucleosomes is found in lung cancer in univariate analyses, but not in multivariate analyses.
  • In addition, therapy outcome is already indicated by the nucleosomal course during the first week of chemo- and radiotherapy in patients with lung, pancreatic, and colorectal cancer as well as in hematologic malignancies.
  • Despite their non-tumor-specificity, kinetics of nucleosomes are valuable markers for the early estimation of therapeutic efficacy and may be helpful to adapting early cancer therapy in the future.
  • [MeSH-minor] Biomarkers, Tumor / blood. Diagnosis, Differential. Humans. Prognosis

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18837945.001).
  • [ISSN] 1749-6632
  • [Journal-full-title] Annals of the New York Academy of Sciences
  • [ISO-abbreviation] Ann. N. Y. Acad. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Macromolecular Substances; 0 / Nucleosomes
  • [Number-of-references] 68
  •  go-up   go-down


100. Balansky R, Ganchev G, Iltcheva M, Steele VE, De Flora S: Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice. Carcinogenesis; 2009 Aug;30(8):1398-401
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prenatal N-acetylcysteine prevents cigarette smoke-induced lung cancer in neonatal mice.
  • We also showed that the antioxidant N-acetylcysteine (NAC) prevents the extensive nucleotide and gene expression alterations that occur 'physiologically' at birth in mouse lung.
  • The present study was designed to evaluate whether administration of NAC during pregnancy may affect the yield of tumors in mice exposed to MCS, starting after birth and continuing for 120 days.
  • In contrast, as much as the 61.1% (33/54) of MCS-exposed mice born from untreated dams had lung tumors, including both benign tumors and bronchoalveolar carcinomas.
  • Treatment with NAC during pregnancy strikingly inhibited the formation of benign lung tumors and totally prevented occurrence of carcinomas.
  • These findings demonstrate for the first time that treatment during pregnancy with an antioxidant chemopreventive agent can affect the induction of tumors consequent to exposure to a carcinogen after birth.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Smoking.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. N-ACETYLCYSTEINE .
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mutat Res. 2003 Nov;544(2-3):441-9 [14644347.001]
  • [Cites] FASEB J. 2003 Jun;17(9):1127-9 [12709406.001]
  • [Cites] Toxicol Lett. 2004 Mar 14;148(1-2):1-9 [15019083.001]
  • [Cites] Toxicol Appl Pharmacol. 2004 Sep 1;199(2):85-90 [15313581.001]
  • [Cites] Chem Biol Interact. 1988;68(3-4):259-71 [3214887.001]
  • [Cites] Ann Emerg Med. 1991 Oct;20(10):1069-72 [1928876.001]
  • [Cites] Carcinogenesis. 1993 Aug;14(8):1545-8 [8353839.001]
  • [Cites] Life Sci. 1994;54(26):2055-9 [8208062.001]
  • [Cites] Anticancer Res. 1995 May-Jun;15(3):839-45 [7645968.001]
  • [Cites] FASEB J. 2005 Mar;19(3):470-2 [15634872.001]
  • [Cites] Exp Lung Res. 2005 Jan-Feb;31(1):3-18 [15765916.001]
  • [Cites] Carcinogenesis. 2005 Sep;26(9):1488-92 [15930027.001]
  • [Cites] South Med J. 2005 Nov;98(11):1118-22 [16351032.001]
  • [Cites] Int J Oncol. 2006 Sep;29(3):521-9 [16865267.001]
  • [Cites] Carcinogenesis. 2006 Oct;27(10):2116-23 [16704990.001]
  • [Cites] Am J Physiol Lung Cell Mol Physiol. 2006 Nov;291(5):L1101-11 [16861382.001]
  • [Cites] DNA Repair (Amst). 2006 Nov 8;5(11):1392-7 [16916625.001]
  • [Cites] Cancer Res. 2007 Feb 1;67(3):1001-6 [17283132.001]
  • [Cites] Hum Exp Toxicol. 2007 Feb;26(2):99-103 [17370867.001]
  • [Cites] Carcinogenesis. 2007 Oct;28(10):2236-43 [17522065.001]
  • [Cites] Mutat Res. 2008 Jul-Aug;659(1-2):137-46 [18155953.001]
  • [Cites] Carcinogenesis. 2008 Aug;29(8):1581-6 [18635525.001]
  • [Cites] Mutat Res. 2008 Sep 26;644(1-2):38-42 [18640134.001]
  • [Cites] Int J Cancer. 2008 Dec 1;123(11):2497-502 [18770867.001]
  • [Cites] Carcinogenesis. 2009 Feb;30(2):315-20 [19073876.001]
  • [Cites] Oncol Rep. 2009 Sep;22(3):469-74 [19639190.001]
  • [Cites] Carcinogenesis. 2001 Jul;22(7):999-1013 [11408342.001]
  • [Cites] Oncogene. 2004 Feb 5;23(5):1166-76 [14647414.001]
  • (PMID = 19458036.001).
  • [ISSN] 1460-2180
  • [Journal-full-title] Carcinogenesis
  • [ISO-abbreviation] Carcinogenesis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CN / N01-CN53301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Free Radical Scavengers; WYQ7N0BPYC / Acetylcysteine
  • [Other-IDs] NLM/ PMC2718074
  •  go-up   go-down






Advertisement